[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 97 of about 97
1. Singh S, Gupta P, Khanna R, Khanna AK: Simultaneous breast and ovarian metastasis from gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2010 Oct;9(5):553-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
  • BACKGROUND: Gallbladder carcinoma is a common malignancy in the Indian subcontinent.
  • A common extra-abdominal site of metastasis is the lungs.
  • Simultaneous metastasis to breast and ovary is extremely rare.
  • METHOD: This report describes an unusual case of carcinoma gallbladder metastasizing to the breast and ovary at the same time.
  • Ultrasound of the abdomen revealed hepatomegaly with thick-walled gallbladder with multiple stones and a mass at the fundus, but normal uterus and ovary.
  • Contrast-enhanced computer tomography of the abdomen showed a gallbladder mass infiltrating the liver parenchyma.
  • Histopathological examination revealed a poorly-differentiated adenocarcinoma with mar-gins free from tumor infiltration.
  • One month after surgery she developed a breast lump.
  • Ultrasound of the abdomen for metastatic workup revealed an ovary mass.
  • Simple mastectomy and salphingo-opherectomy were performed, and histopathological examination revealed a metastatic adenocarcinoma.
  • The patient is now on chemotherapy with gemcitabin.
  • CONCLUSION: This is an unusual case of carcinoma of the gallbladder with metastasis to the breast and ovary, which has not been documented before.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cholecystectomy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Ovariectomy. Salpingectomy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943468.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


2. Fortin D, Gendron C, Boudrias M, Garant MP: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer; 2007 Feb 15;109(4):751-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
  • BACKGROUND: Cerebral metastases are clinically significant in 10% to 30% of patients with neoplasia.
  • There is no consensus on the role of enhanced chemotherapy delivery as an adjuvant treatment modality in this disease.
  • In this report, the authors detailed their experience with intraarterial (IA) chemotherapy infusion with and without blood-brain barrier disruption (BBBD) in patients with multiple cerebral metastases.
  • Mean and median survival obtained was as follows: 34 and 29.6 months for the whole group; 33.6 and 42.3 months for ovarian carcinoma; 15.3 and 13.5 months for lung adenocarcinomas; 8.3 and 8.8 months for small cell lung carcinoma; 8.9 and 8.1 months for breast carcinoma; and 24.8 and 16.3 months, respectively, for cerebral metastasis from systemic lymphoma.
  • CONCLUSIONS: Even with a small number of patients in each subgroup, the results obtained seem promising for multiple brain metastasis of ovarian carcinoma, adenocarcinoma of lung, small cell lung carcinoma, and systemic lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Infusions, Intra-Arterial
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphoma / drug therapy. Lymphoma / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Osmosis / drug effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17211866.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report).
  • The metastasis of malignant tumors to the oral cavity remains a rare clinical entity.
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • Herein, we describe an unusual case of ovarian mucinous cystadenocarcinoma that metastasized to the mandibular gingiva as an initial manifestation.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A patient was a 54-year-old woman who developed the paresthesia and swelling of the right mandible after tooth extraction.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • A positron emission tomography and computed tomography using 18F-fluorodeoxyglucose depicted an ovarian tumor with multiple pelvic and paraaortic lymph node swellings.
  • A magnetic resonance imaging (MRI) clearly demonstrated the presence of an ovarian cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • She has been treated with adjuvant chemotherapy consisting of paclitaxel and carboplatin.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biopsy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Positron-Emission Tomography. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • They have a generally poor prognosis and often develop recurrent disease.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


5. Tiwari A, Kumar N, Bajpai R, Lal P: Bone metastasis from ovarian cancer. J Cancer Res Ther; 2007 Jan-Mar;3(1):34-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis from ovarian cancer.
  • We report a case of epithelial ovarian cancer, which presented with lumbar vertebral metastasis soon after treatment, as a part of distant spread.
  • This patient was then treated by palliative radiotherapy and put on second line chemotherapy i.e, Topotecan.
  • She responded to treatment well.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / secondary. Liver Neoplasms / secondary. Lumbar Vertebrae. Ovarian Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Topotecan / administration & dosage


6. Yuan Y, Qin L, Liu D, Wu RC, Mussi P, Zhou S, Songyang Z, Xu J: Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. Cancer Res; 2007 Sep 1;67(17):8032-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.
  • The genetic changes and mechanisms underlying the progression of estrogen-dependent breast cancers to estrogen-independent, antiestrogen-resistant, and metastatic breast cancers are unclear despite being a major problem in endocrine therapy.
  • To identify genes responsible for this progression, we carried out a genetic screening by an enhanced retroviral mutagen (ERM)-mediated random mutagenesis in the estrogen-dependent T47D breast cancer cells.
  • An ERM insertion into the p27 locus of T47D cells disrupted the p27 gene and created estrogen-independent and antiestrogen-resistant breast cancer cells that still maintained functional estrogen receptors.
  • First, CDK2 activity was increased in the absence of estrogen or in the presence of estrogen antagonists tamoxifen or ICI 182780; second, amplified in breast cancer 1 (AIB1), a cancer overexpressed transcriptional coactivator, was hyperphosphorylated, which made AIB1 a better coactivator for E2F1; and third, growth factor receptor binding protein 2-associated binder 2 (Gab2) and Akt activity were increased following E2F1 overactivation, leading to a significant enhancement of cell migration and invasion.
  • Furthermore, the p27-deficient cells, but not T47D control cells, developed lung metastasis in an ovarian hormone-independent manner when they were i.v. injected into nude mice.
  • In sum, loss of p27 activated AIB1, E2F1, Gab2, and Akt; increased cell migration and invasion; caused antiestrogen insensitivity; and promoted metastasis of breast cancer cells.
  • These findings suggest that p27 plays an essential role in restriction of breast cancer progression.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S [12538499.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):179-86 [12790780.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1681-92 [12805412.001]
  • [Cites] Cell Growth Differ. 2000 Feb;11(2):99-110 [10714766.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9042-6 [10908655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13549-54 [11087842.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):5964-72 [11146547.001]
  • [Cites] Breast Cancer Res. 2001;3(2):91-4 [11250752.001]
  • [Cites] Circulation. 2001 Jun 19;103(24):2967-72 [11413088.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3695-702 [11439332.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6583-91 [11522658.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1877-85 [11532967.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40888-95 [11527971.001]
  • [Cites] Oncology. 2001;61 Suppl 2:73-82 [11694791.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8390-2 [11731414.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47675-83 [11590147.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11293-8 [12151601.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1145-52 [12244301.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1136-44 [12244303.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):216-28 [12482975.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):41-7 [12507555.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 14):12-22 [14513433.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41355-66 [12904306.001]
  • [Cites] Breast Cancer Res. 2004;6(1):55-7 [14680486.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1875-85 [14996752.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):55-66 [15082918.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5157-71 [15169882.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):926-35 [15199112.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • [Cites] Mol Cell. 2004 Sep 24;15(6):937-49 [15383283.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(3):267-85 [8573710.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):5-12 [8554983.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(1):57-66 [8825123.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] Nat Med. 1997 Feb;3(2):227-30 [9018244.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8299-308 [15548698.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):51-63 [15652749.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7993-8002 [16140972.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2162-72 [16489017.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3105-19 [16916939.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11623-31 [17178856.001]
  • [Cites] J Urol. 2003 Mar;169(3):1122-33 [12576866.001]
  • (PMID = 17804714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84208; United States / NIDDK NIH HHS / DK / DK58242; United States / NCI NIH HHS / CA / CA112403; United States / NCI NIH HHS / CA / R01 CA112403-02; United States / NCI NIH HHS / CA / R01 CA084208; United States / NCI NIH HHS / CA / CA112403-02; United States / NCI NIH HHS / CA / CA119689; United States / NCI NIH HHS / CA / R01 CA112403; United States / NIDDK NIH HHS / DK / R01 DK058242; United States / NCI NIH HHS / CA / R01 CA119689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Mutant Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ NIHMS50377; NLM/ PMC2412956
  •  go-up   go-down


7. McCormick CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE: The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol; 2007 Jun;105(3):791-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for colon cancer metastatic to the ovary.
  • OBJECTIVE: We sought to further elucidate the survival impact of cytoreductive surgery among patients with colon cancer metastatic to the ovary.
  • METHODS: All women diagnosed with primary colon cancer metastatic to the ovary at a single institution from 1980 to 2005 were retrospectively identified.
  • RESULTS: A total of 39 patients with 40 cases of colon cancer metastatic to the ovary were identified.
  • Patients with metastatic disease confined to the ovaries (n=11) had a median overall survival (OS) time of 61 months (range 15-120) compared to 17 months (range 0.5-73) for those with more extensive metastases (n=24) (p=0.0428).
  • Patients undergoing optimal cytoreduction (residual < or =1 cm) had a median progression-free survival (PFS) of 11 months (range 0.5-120, n=26) compared to 2.5 months (range 0.5-12, n=9) for those receiving suboptimal cytoreduction (p=0.0001).
  • All major complications occurred in women with diffuse disease who underwent extensive cytoreductive surgery.
  • CONCLUSIONS: The observation that optimal cytoreduction was associated with prolonged PFS and OS in both patients with localized ovarian and widespread metastases of colon cancer suggests a role for surgical management of metastatic colon cancer in women.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408727.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Sasaki H, Idani F, Asami S, Komoto S, Kubota T, Kumano K, Kurose Y, Kubo S, Nojima H, Yoshioka T, Muro M, Kin H, Takakura N: [A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2478-80
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].
  • We report a long-term survival case treated by chemotherapy with new anticancer drugs such as S-1, CPT-11 and docetaxel after bilateral overiectomy for bilateral ovarian metastases of progressive gastric cancer.
  • A 68-year-old female, who had undergone total gastrectomy with D2 lymphadenectomy for scirrhous gastric cancer of Stage IIIA, was admitted because of ovarian metastasis.
  • Laparoscopic bilateral ovariectomy was performed for ovarian metastases of the gastric cancer (Krukenberg tumor) 6 months after gastrectomy.
  • Seven months after gastrectomy, 11-course of S-1 treatment (80 mg/m2) for bilateral ovarian metastases of the gastric cancer was administered.
  • Then, the drug was changed to docetaxel (60 mg/m2).
  • After 9-course of docetaxel treatment, the mediastinal lymphadenopathy disappeared.
  • For a treatment of grade 3 neuropathy, a 12-course CPT-11 was started after gastrectomy 3 years and 6 months ago.
  • CT scan and PET-CT showed no new metastasis in 4 years and 10 months after gastrectomy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Krukenberg Tumor / drug therapy. Krukenberg Tumor / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Female. Gastrectomy. Humans. Ovariectomy. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224612.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Bloch-Marcotte C, Ambrosetti D, Novellas S, Caramella T, Dahman M, Thyss A, Chevallier P: Ovarian metastasis from choroidal melanoma. Clin Imaging; 2008 Jul-Aug;32(4):318-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis from choroidal melanoma.
  • Ocular melanoma has a strong tendency to metastasize often several years after its initial diagnosis was made.
  • We report on the case of a 50-year-old woman who was treated 20 years earlier for an ocular melanoma and currently seen regularly in our institute for liver metastases that were treated by chemotherapy.
  • After three treatments, a check-up with computed tomography demonstrated the presence of a right ovarian mass.
  • An ovariectomy was performed, and the pathological examination confirmed the diagnosis of an ovarian metastasis from an ocular melanoma.
  • This is the fourth case of metastasis to the ovary from an ocular melanoma reported in the medical literature.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603189.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sakakura C, Hagiwara A, Yoshikawa T, Hamada T, Yamagishi H: Huge ovarian metastasis from jejunal cancer occurring immediately after initial operation. Hepatogastroenterology; 2005 Mar-Apr;52(62):425-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge ovarian metastasis from jejunal cancer occurring immediately after initial operation.
  • Correct preoperative diagnosis of jejunal cancer is difficult, and there are no clear guidelines for the postoperative follow-up to monitor the recurrence of jejunal cancer.
  • This report describes asynchronous ovarian metastasis from jejunal cancer occurring after initial operation.
  • The patient was a 68-year-old postmenopausal woman with a preoperatively correctly diagnosed jejunal cancer.
  • Three months later, vaginal bleeding and a large metastasis in the left ovary were detected, for which a left oophorectomy was performed.
  • Peritoneal dissemination was also detected perioperatively, so that chemotherapy with 5-FU/leukovoline was started.
  • Our case demonstrates that it is necessary to pay careful attention to synchronous or non-synchronous metastases to the ovaries after operation for jejunal cancer in females.
  • Consideration should also be given to the efficacy of oophorectomy for ovarian metastases and of intensive chemotherapy combined with jejunal resection for carcinoma because of the poor prognosis of these treatment modalities.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Jejunal Neoplasms / pathology. Jejunal Neoplasms / surgery. Ovarian Neoplasms / secondary
  • [MeSH-minor] Angiography. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Ovariectomy. Peritoneum / pathology. Postoperative Period. Radiography, Abdominal. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816449.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Milingos D, Doumplis D, Savage P, Seckl M, Lindsay I, Smith JR: Placental site trophoblastic tumor with an ovarian metastasis. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):925-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor with an ovarian metastasis.
  • Placental site trophoblastic tumors (PSTT) are the rarest form of gestational trophoblastic disease (GTD).
  • The most common metastatic sites are the lung, liver, and vagina while spread to the adnexa is relatively unusual.
  • We describe a case of a 35-year-old woman presenting with PSTT and ovarian metastasis who was successfully treated with radical hysterectomy, bilateral oophorectomy, pelvic lymph node dissection, and postoperative chemotherapy.
  • The case highlights the possibility of ovarian metastases despite normal preoperative imaging and confirms the value of multidisciplinary management of this rare illness.
  • [MeSH-major] Ovarian Neoplasms / secondary. Trophoblastic Tumor, Placental Site / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Pregnancy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343608.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lee SJ, Lee J, Lim HY, Kang WK, Choi CH, Lee JW, Kim TJ, Kim BG, Bae DS, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. Cancer Chemother Pharmacol; 2010 Jul;66(2):229-35
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis.
  • PURPOSE: A recent study demonstrated that colorectal cancer (CRC) with ovarian metastases was less responsive to chemotherapy compared with extraovarian metastases.
  • Hence, the ovary may actually represent a "sanctuary" for metastatic cells from CRC.
  • The aim of the study was to investigate the impact of ovarian metastatectomy on survival of CRC patients with ovarian metastasis.
  • For the historical control, 47 CRC patients with ovarian metastasis without resection were included in the analysis.
  • The proportion of synchronous metastasis was higher in the oophorectomy group than in the control group (57 vs. 30%; P = 0.003).
  • For ovary-specific survival (date of ovarian metastasis diagnosis to death), CRC patients with an oophorectomy showed a significantly more favorable survival rate than the control group (20.8 vs. 10.9 months; P < 0.001).
  • In univariate analyses, oophorectomy (P = 0.038), unilaterality of ovarian metastasis (P = 0.032), metastasis confined to ovaries (P < 0.001), normal CEA level (P < 0.001), good performance status (P = 0.001), palliative chemotherapy (P = 0.001), and primary disease resection (P = 0.005) were identified as significantly good prognostic factors for overall survival.
  • The oophorectomy, chemotherapy, metastasis confined to ovaries, normal CEA level, and good performance status retained statistical significance at the multivariate level (P = 0.003, P = 0.004, P = 0.005, P = 0.015, and P = 0.029, respectively).
  • CONCLUSIONS: Based on this retrospective analysis, the ovarian metastatectomy significantly prolonged survival in CRC patients with ovarian metastases.
  • The potential role of an ovarian metastatectomy in the management of CRC should be prospectively studied.
  • [MeSH-major] Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovary / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Factor Analysis, Statistical. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Ovariectomy. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820936.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


13. Zehetleitner G, Thiel I, Petru E: Long-term disease-free survival after breast cancer metastatic to the ovary. Int J Gynecol Cancer; 2002 May-Jun;12(3):317-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term disease-free survival after breast cancer metastatic to the ovary.
  • The prognosis of patients with breast cancer symptomatically metastatic to the ovary is almost uniformly poor.
  • In this case report, we present a 33-year-old para-4 with a symptomatic metastasis to the ovary.
  • Previously, a modified radical mastectomy with adjuvant radiotherapy had been performed for invasive ductal carcinoma of the left breast.
  • Laparotomy showed a 13-cm tumor of the left ovary; frozen section histology showed malignancy consistent with the previous breast cancer.
  • The patient received adjuvant combination chemotherapy.
  • About 5 years later, a carcinoma of the right breast was treated with conservative surgery and adjuvant radiation and chemotherapy.
  • At the last follow-up, more than 13 years after the first breast cancer and 12 years after the ovarian metastasis, the patient was alive and well without evidence of disease.
  • Bilateral oophorectomy is a therapeutic option in premenopausal patients with localized or advanced breast cancer.
  • Our patient experienced long-term disease-free survival following an isolated metastasis to one ovary.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Laparotomy. Mastectomy, Radical. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060456.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Imamura H, Kishimoto T, Kawabata R, Furukawa H, Fukunaga M, Ohzato H, Miyanishi K, Yamamoto T, Miwa H: [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2490-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection].
  • The patient was a 51-year-old female, who underwent radical surgery for cancer of remnant stomach in May 2006 (f-T4N0M0P0H0CY0, por 2, Stage IIIA, Cur B).
  • Bilateral ovarian resection was performed in March 2009 for bilateral ovarian metastasis, so called "Krukenberg tumor" with peritoneal dissemination detected with CT scan after one-year adjuvant chemotherapy with S-1 (80 mg/m2, 4 weeks on and 2 weeks off).
  • As of June 2010, she is alive and maintain her status quo after 6 courses of S-1 plus CDDP combination therapy (S-1 80 mg/m2, 3 weeks on, CDDP 60 mg/m2, started at day 8, ended 35 days later) followed by S-1 for residual peritoneal dissemination detected at operation.
  • In ovary metastasis of gastric cancer, even if accompanied by peritoneum metastasis, ovarian resection as a reduction surgery followed by chemotherapy may improve survival.
  • [MeSH-major] Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Gastrectomy. Humans. Middle Aged. Ovariectomy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224616.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Niu X, Peng Z, Ding S, Yang K: [The effect of intraperitoneal chemotherapy on retroperitoneal lymph node metastasis of ovarian cancer]. Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun;31(2):188-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effect of intraperitoneal chemotherapy on retroperitoneal lymph node metastasis of ovarian cancer].
  • The objective of this study was to investigate the effect of intraperitoneal chemotherapy(repeated injections of cisplatin in small doses during a short time) on retroperitoneal lymph node metastasis of ovarian cancer.
  • Thirty patients with ovarian cancer were selected and divided into two groups.
  • The patients in the first group received intraperitoneal chemotherapy only once (48 hours before operation); the patients in the second group received intraperitoneal chemotherapy twice (96 hours and 48 hours before operation).
  • After the intraperitoneal chemotherapy, according to the predicted time, the Pt concentrations of the tissues were measured by flameless atomic absorption spectrometry; the pathologic examinations of the lymph nodes were carried out.
  • The results showed that the drug concentrations of the aortic, obturator and iliac lymph nodes of the first group were not significantly different, neither were the drug concentrations of the lymph nodes of the second group.
  • The drug concentrations of the lymph nodes of the first and the second groups were 2.06 and 1.91 times that of the surrounding tissues respectively.
  • Also, the drug concentrations of peritoneum of the first and the second groups were 4.14 and 2.50 times that of the lymph nodes.
  • The drug concentrations of the iliac, obturator and aortic lymph nodes of the second group were 2.27, 2.75 and 2.54 times that of the first group (P < 0.005).
  • Under light microscope, the metastatic cancer tissues in lymph nodes showed liquefaction necrosis in the second group.
  • The results indicate that small doses of cisplatin given by repeated injections during a short time can lead to drug accumulation and consequently high efficacy with low toxicity, suggesting that this method may be used for the treatment of lymphatic metastasis of ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12515132.001).
  • [ISSN] 0257-7712
  • [Journal-full-title] Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao
  • [ISO-abbreviation] Hua Xi Yi Ke Da Xue Xue Bao
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Huang SY, Jung SM, Ng KK, Chang YC, Lai CH: Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol; 2005 May;97(2):652-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
  • BACKGROUND: There have been several reports about successful fertility-preserving treatment of endometrial carcinoma with subsequent pregnancy.
  • However, conservative hormonal treatment for early-stage endometrial cancer still entails some risk.
  • CASE: We present a 36-year-old nulliparous woman, initially diagnosed as clinical stage IA, grade 1 endometrial adenocarcinoma, receiving 6-month conservative treatment with remission achieved at 4 months from diagnosis.
  • Recurrence at the endometrium was documented at the end of treatment.
  • She underwent a definitive surgery including total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection.
  • The final pathology revealed well-differentiated endometrioid adenocarcinoma with inner one-third myometrial invasion and right ovarian metastasis.
  • CONCLUSION: This case report signals a warning that negative preoperative imaging studies are not reassuring for a relapsing low-grade, early-stage endometrial carcinoma failing conservative treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Megestrol Acetate / therapeutic use. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


17. Lee S, Lee J, Ahn H, Park J, Kim J, Park K, Lim H, Kang W, Kim B, Park Y: The role of oophorectomy for colon cancer with ovarian metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):e15113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of oophorectomy for colon cancer with ovarian metastasis.
  • : e15113 Background: A recent study demonstrated that colorectal cancer with ovarian metastases were less responsive to chemotherapy compared to extraovarian metastases.
  • Hence, the ovary may actually represent a "sanctuary" for metastatic cells from CRC.
  • The aim of the study was to investigate the impact of oophorectomy on survival of colorectal cancer patients with ovarian metastasis.
  • METHODS: Between 1996 and 2008, 83 colorectal cancer patients underwent oophorectomy.
  • For the historical control, 47 colorectal cancer patients without oophorectomy were included in the analysis.
  • The proportion of synchronous metastasis was higher in the oophorectomy than the control group (57% vs 30%, respectively; P=.003).
  • For ovary-specific survival (date of ovarian metastasis diagnosis to death), colorectal cancer patients with oophorectomy showed significantly favorable survival than the control group (20.8 vs 10.9 months, respectively; P<.001).
  • At univariate analyses, no oophorectomy (P=.038), bilaterality of ovarian metastasis (P=0.032), the presence of extraovarian metastasis (P<0.001), elevated CEA (p<0.001), poor performance status (p=0.001), no palliative chemotherapy(p=0.001), no primary disease resection(p=0.005) were identified as significantly poor prognostic factors for overall survival.
  • The no oophorectomy, no chemotherapy, extraovarian metastasis, elevated CEA, poor performance status retained statistical significance at multivariate level. (p=0.003, p=0.004, p=0.005, p=0.015, p=0.029, respectively).
  • CONCLUSIONS: Based on this retrospective analysis, the oophorectomy significantly prolonged survival in colorectal cancer patients with ovarian metastases.
  • A potential role of oophorectomy in the management of colorectal cancer should be prospectively studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Song H, Kim J, Do Y, Lee W, Ryu S, Kim I, Sohn S: The clinical significance of oophorectomy in gastric patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15646 Background: The oophorectomy in isolated metastasis of ovary can lead to long term survival in patients with gastric cancer, but the clinical significance of oophorectomy in stage IV gastric cancer patients is not known well in this time.
  • METHODS: We reviewed the medical record of the 55 gastric cancer patients who were metastasis or recurrent in ovary at Dongsan Medical Center, Kimyung University School of Medicine, Daegu, Korea from 1985 to 2008.
  • RESULTS: Twenty-one patients were metastasis to ovary at the time of diagnosis of gastric cancer, and 34 patients were recurrent in ovary after the gastric resection.
  • The mean age was 45.3 ± 11.6 years in metastatic cancer and 46.8 ±12.6 years in recurrent cancer patients.
  • The stage at the time of gastric resection in 34 recurrent patients were I in 3, II in 1, III in 18, and IV in 10.
  • Adjuvant chemotherapy were performed in 26 (76.5%) patients.
  • Oophorectomy were performed in 33 (97.1%) of recurrent cancer, and 17 (81.0%) of metastatic cancer.
  • The 1-year and 2-year survival rate of metastatic cancer were 14.7%, and 0%, and 1-year, 2-year, and 3-year survival rate of recurrent cancer were 47.2%, 18.1%, and 0%, respectively.
  • The median survival duration of metastatic cancer were 8.9 ±1.0 months, and recurrent cancer were 11.4 ±2.3 months.
  • Recurrent cancer were better survival than metastatic cancer patients (p=0.014).
  • The long-term survival (over 2 years) was noted in 5 patients of recurrent cancer patients.
  • The stage of gastric cancer was correlated to overall survival time in total patients (p=0.028).
  • But, the relapse-free survival time after gastrectomy is the only factor to predict survival duration after oophorectomy in recurrent cancer patients (p=0.029).
  • Age, stage of gastric cancer, extent of involvement of ovary, and systemic chemotherapy were not related to survival time of recurrent cancer patients.
  • CONCLUSIONS: The survival time in patients with oophorectomy in recurrent gastric cancer was correlated to relapse-free survival time after gastric resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jeremić K, Berisavac M, Argirović R, Gojnić M, Bosković V, Milenković V, Mostić T: Solitary ovarian metastasis from cutaneous melanoma--case report. Eur J Gynaecol Oncol; 2006;27(4):443-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary ovarian metastasis from cutaneous melanoma--case report.
  • A 47-year-old patient with two previous deliveries and three deliberate abortions was admitted to the Institute of Gynecology and Obstetrics, Clinical Center of Serbia with the diagnosis of a uterine myoma and left adnexal mass.
  • Five years previously, she had undergone excision of a malignant melanoma from her left leg.
  • After ultrasound and computed tomography examination, the patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, intracolic omentectomy and selective pelvic lymphonodectomy.
  • The final histopathological diagnosis was metastatic amelanotic malignant melanoma of the left ovary and uterine myomas.
  • After surgery the patient was transferred to the Institute of Oncology and Radiology where she received chemotherapy.
  • [MeSH-major] Melanoma / secondary. Ovarian Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009650.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


20. Nishimura T, Maeda Y, Okada T, Nakamura M, Sakata K, Setoguchi M, Kawasaki N: [Ovarian metastasis after complete response of colon cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2263-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian metastasis after complete response of colon cancer].
  • We report a case of ovarian metastasis after complete response of colon cancer.
  • A 55-year-old woman underwent a sigmoidectomy for sigmoid colon cancer with hepatic metastasis and para-aorta lymph node metastasis.
  • After the operation, the patient was given chemotherapy with bevacizumab+mFOLFOX6.
  • Thirteen months after the operation, right ovarian tumor was found and bilateral oophrectomy, hysterectomy and omentectomy were performed.
  • Histopathologically the ovarian tumor was metastasized from colonic cancer.
  • After the second operation, the patient was given chemotherapy with bevacizumab+FOLFIRI.
  • At present, the patient remains disease-free for 6 months after the ovarian operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037390.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


21. Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2542-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy].
  • An 80-year-old female patient was undergone sigmoidectomy with D2 lymph node dissection for type 2 sigmoid colon cancer in February 2007.
  • A post operative pathological finding of cancer was SS, N0, P0, H0, M0 (Stage II), curative A.
  • CT scan and MRI revealed a mass of 10 cm in diameter with multiple cysts in the pelvic cavity, which was diagnosed a malignant ovarian tumor.
  • In May 2008, total hysterectomy, bilateral oophorectomy, and partial omentectomy were performed and its pathological finding was metastatic ovarian tumor originating from colon cancer.
  • Adjuvant chemotherapy was administered, as cancer cells were detected in the ascites.
  • [MeSH-major] Adenocarcinoma / pathology. Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Combinations. Female. Humans. Hysterectomy. Ovariectomy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224633.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


22. Yilmaz Z, Bese T, Demirkiran F, Ilvan S, Sanioglu C, Arvas M, Kosebay D: Skin metastasis in ovarian carcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:414-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastasis in ovarian carcinoma.
  • We report a case of 69-year-old woman who presented with pleural metastasis of a serous papillary adenocarcinoma of the ovary.
  • After chemotherapy and surgery, she had 2 years disease-free survival.
  • After this period of time, she presented with a swollen leg, a cellulitis-like syndrome and erythematous nodules at lower abdominal wall and upper leg skin.
  • The skin biopsy revealed metastasis of adenocarcinoma in the dermis.
  • She died after 4 months of the diagnosis of the skin metastasis.
  • In 20 years experience in our unit, it is the first time that we recognize a cutaneous metastasis in ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / pathology. Pleural Neoplasms / secondary. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Disease-Free Survival. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515636.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Garin L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul JL: Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci; 2002 Dec;47(12):2760-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
  • All pathology specimens exhibited an adenocarcinomatous component associated with carcinoid proliferation related to an appendicular tumor leading to the diagnosis of appendicular adenocarcinoid with ovarian, peritoneal, and nodal metastases.
  • The patient's general status worsened rapidly with widespread nodal metastasis.
  • Chemotherapy (Folfox 4 regimen) was given, and the patient improved within six weeks.
  • Presently, more than three years after the end of the treatment, the patient is still alive and in complete remission.
  • These tumors exhibit two cellular components.
  • Ovarian metastasis is frequent.
  • Prognosis is intermediate between adenocarcinoma and malignant carcinoid.
  • When given to patients with colonic carcinoma, the Folfox regimen used effectively here, is associated with a 50% objective response but complete response is very exceptional.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds. Ovarian Neoplasms / secondary

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • [Cites] J Surg Oncol. 1997 Sep;66(1):51-3 [9290693.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Surgery. 1992 Mar;111(3):244-50 [1542852.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 12498298.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


24. Toiyama Y, Inoue Y, Hiro J, Ojima E, Watanabe H, Miki C, Kusunoki M: Alteration of the chemoresistant gene expression during chemotherapy for colon cancer: a molecular case report. Oncol Rep; 2008 Mar;19(3):755-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of the chemoresistant gene expression during chemotherapy for colon cancer: a molecular case report.
  • Chemotherapy remains the main choice of treatment for the management of unresectable or metastatic colorectal cancer.
  • However, drug resistance is a major problem, limiting the effectiveness of the chemotherapies presently used to treat cancer.
  • During treatment, drug resistance can also be acquired by tumors that are initially sensitive to chemotherapy.
  • We present a case of metachronous splenic recurrence after a curative resection of appendical cancer with ovarian metastasis, although the patient had been treated with 5-FU/LV followed by mFOLFOX6 after surgery.
  • Molecular analyses by RT-PCR also showed that the residual tumor after chemotherapy has cancer cells overexpressing 5-FU/l-OHP based chemotherapy-resistant genes.
  • Therefore, it was suggested that a careful assessment of the disease status be undertaken during chemotherapy to ensure that the possibility of surgical resection, especially of the re-growth or partial response tumors, was not missed, since several genes, chemoresistant to the agents used, can be induced in residual tumors during chemotherapy.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Drug Resistance, Neoplasm / genetics
  • [MeSH-minor] Aged. Combined Modality Therapy. Enzymes / genetics. Enzymes / metabolism. Female. Humans. RNA, Messenger / metabolism. Splenic Neoplasms / pathology. Splenic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288412.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzymes; 0 / RNA, Messenger
  •  go-up   go-down


25. Otrock ZK, Seoud MA, Khalifeh MJ, Makarem JA, Shamseddine AI: Laparoscopic splenectomy for isolated parenchymal splenic metastasis of ovarian cancer. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1933-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic splenectomy for isolated parenchymal splenic metastasis of ovarian cancer.
  • Metastatic carcinoma of the spleen occurs in a setting of widespread malignant disease.
  • Solitary parenchymal splenic metastasis of ovarian carcinoma is rare.
  • We report a case of a 59-year-old woman who presented with an elevated serum CA125 level due to a solitary splenic metastasis after a long disease-free period.
  • She was treated with laparoscopic splenectomy followed by chemotherapy.
  • The literature contains 16 cases of solitary parenchymal splenic metastasis of ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009994.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


26. Nakayama N, Tanabe S, Koizumi W, Higuchi K, Sasaki T, Nakatani K, Shimoda T, Nishimura K, Kobayashi N, Mitomi H, Saigenji K: [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1641-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
  • Computed tomography and ultrasonography of the abdomen revealed bilateral ovarian tumors, massive ascites, and bilateral pleural effusion.
  • Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy.
  • She received 3 courses of combination chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin.
  • Chemotherapy was repeated after surgery.
  • Lymph-node metastasis recurred 1 year 8 months after the start of chemotherapy.
  • Treatment was switched to irinotecan plus cisplatin, and the lymph nodes shrank.
  • Two years 10 months after starting chemotherapy, abdominal and low back pain developed.
  • Bone scintigraphy revealed bone metastasis.
  • The patient responded to radiotherapy with chemotherapy (cisplatin plus 5-fluorouracil).
  • Subsequently, abdominal computed tomography showed lymph-node swelling, multiple metastases to the liver, ascites, and a right pleural effusion.
  • She was readmitted to the hospital and received intraperitoneal chemotherapy with cisplatin.
  • The patient survived for about 3 years 4 months after the start of treatment.
  • Chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin may thus be an effective therapeutic option in patients who have advanced gastric cancer with peritoneal dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Krukenberg Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pleurisy / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Hysterectomy. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Methotrexate / administration & dosage. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Pancreatectomy. Survivors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Einat S, Amir S, Silvia M, Moshe I: Successful laparoscopic removal of a solitary adrenal metastasis from ovarian carcinoma: a case report. Gynecol Oncol; 2002 Apr;85(1):201-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful laparoscopic removal of a solitary adrenal metastasis from ovarian carcinoma: a case report.
  • BACKGROUND: The adrenal gland is a site of metastatic spread of some tumors.
  • Usually the presence of adrenal metastasis signals widespread disease; however, isolated adrenal metastases have been reported.
  • The adrenal gland, along with certain other organs, is considered a pharmacological sanctuary.
  • Several reports describe long-term survival after adrenalectomy due to isolated adrenal metastases, in particular from non-small-cell lung cancer.
  • CASE: We present a rare case of a laparoscopically resected solitary adrenal metastasis originating from ovarian carcinoma.
  • To the best of our knowledge there was no report in the literature of an isolated adrenal metastasis from ovarian carcinoma.
  • The patient described developed an isolated left adrenal metastasis 11 months after completion of adjuvant chemotherapy for stage III ovarian cancer.
  • CONCLUSION: Isolated adrenal metastasis from ovarian cancer is a rare event, never before described in the literature.
  • This case report describes a laparoscopic resection of an adrenal metastasis from ovarian cancer, and the drop of CA125 levels indicated complete resection of the metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925146.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Klasa-Mazurkiewicz D, Narkiewicz J, Milczek T, Lipińska B, Emerich J: Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Gynecol Oncol; 2009 Apr;113(1):91-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.
  • Experimental studies revealed that maspin suppresses tumor growth, angiogenesis, invasion and metastasis.
  • We examined maspin expression in human ovarian tumors and relation between maspin expression and clinicopathological features as well as the role of maspin in predicting clinical outcome in patients with ovarian cancer.
  • METHODS: Tissue samples consisted of 42 benign tumors, 10 borderline (LMP) tumors, 76 ovarian carcinomas, 8 Krukenberg tumors and 32 normal tissues.
  • RESULTS: Relative maspin level was significantly higher in patients with LMP tumors (median 0.74) and early stages ovarian cancers (median 0.46) when compared with healthy tissues (median 0.03), those with benign (median 0.23) and metastatic tumors (median 0.22).
  • Overexpression of maspin was found to correlate with the early stage of the disease (p=0.001), non-serous subtype of ovarian cancer (p=0.03) and positive response to chemotherapy (p=0.02).
  • CONCLUSIONS: Maspin is upregulated in borderline tumors and the early stages of ovarian carcinoma and then significantly downregulated with malignant transformation.
  • High expression may paradoxically promote the invasion and metastasis of ovarian carcinomas.
  • Our study revealed that maspin expression could play an important role in predicting the results of treatment of ovarian cancer patients.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Serpins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Humans. Krukenberg Tumor / drug therapy. Krukenberg Tumor / metabolism. Krukenberg Tumor / pathology. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193429.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


29. Goto Y, Katsumata N, Nakai S, Sasajima Y, Yonemori K, Kouno T, Shimizu C, Ando M, Fujiwara Y: Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. Int J Clin Oncol; 2008 Dec;13(6):555-8
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate.
  • A 60-year-old woman with a history of ovarian carcinoma and complaining of gait instability, dizziness, nausea, and a right temporal headache visited a neurologist.
  • A diagnosis of leptomeningeal metastasis was made, based on the results of a cerebrospinal fluid examination.
  • Although uncommon, the possibility of leptomeningeal metastasis from ovarian carcinoma should be considered; in such cases, treatment with intraventricular methotrexate may be effective and feasible and should be considered as a treatment strategy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Methotrexate / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Feb;41(2):776-83 [630551.001]
  • [Cites] Gynecol Oncol. 1984 May;18(1):119-24 [6714801.001]
  • [Cites] Obstet Gynecol. 1986 Dec;68(6):746-50 [3024084.001]
  • [Cites] J Neurol. 1999 Sep;246(9):810-4 [10525979.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2066-9 [3756821.001]
  • [Cites] Neurology. 1983 Dec;33(12):1565-72 [6685829.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):571-4 [8573536.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):85-99 [16215819.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):519-28 [13678719.001]
  • [Cites] Cancer. 1978 Jul;42(1):283-6 [667799.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):398-406 [3134278.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • (PMID = 19093186.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; AU0V1LM3JT / Gadolinium; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Katase K, Shimizu Y, Kobayashi Y, Hasumi K: [Chemotherapy with combination of UFT and cisplatin against metastatic ovarian tumor originating from gastric cancer]. Gan To Kagaku Ryoho; 2004 Jun;31(6):943-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with combination of UFT and cisplatin against metastatic ovarian tumor originating from gastric cancer].
  • Krukenberg's tumor, an metastatic ovarian tumor originating from gastric cancer, is a disease with extremely poor prognosis, and it is rare for patients to survive for more than 2 years after the diagnosis.
  • We encountered a patient in whom a long-term good prognosis could be obtained probably because of the effects of chemotherapy after the ovarian tumor extraction.
  • Enhancement of the antitumor effects by the concomitant use of 5-FU and cisplatin has been attracting attention, and the methods of administration of these drugs have been investigated by numerous researchers as FP therapy.
  • It was characteristic to the treatment of our patient that 5-FU was administered in the form of oral UFT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Routes. Female. Humans. Hysterotomy. Ovariectomy. Prognosis. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222118.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


31. Terek MC, Ozkinay E, Zekioglu O, Erhan Y, Cagirgan S, Pehlivan M, Mgoyi L: Acute leukemia in pregnancy with ovarian metastasis: a case report and review of the literature. Int J Gynecol Cancer; 2003 Nov-Dec;13(6):904-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia in pregnancy with ovarian metastasis: a case report and review of the literature.
  • Bone marrow biopsy revealed acute lymphocytic leukemia, French American-British L2 subtype B cell immunotype.
  • A left ovarian mass was identified during the cesarean section which later proved to be lymphoblastic infiltration.
  • The patient was started on induction chemotherapy consisting of vincristine, daunorubicin, prednisolone, and l-asparaginase immediately after the diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675333.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Cormio G, Maneo A, Colamaria A, Loverro G, Lissoni A, Selvaggi L: Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases. Gynecol Oncol; 2003 Apr;89(1):116-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases.
  • OBJECTIVE: Central nervous system (CNS) involvement is considered an uncommon complication in patients with ovarian carcinoma.
  • The aim of this study was to evaluate prognostic factors for survival following surgical resection of brain metastases in patients with ovarian carcinoma.
  • METHODS: A retrospective chart review was conducted on 22 patients who had been submitted to neurosurgical resection of a solitary brain metastasis from ovarian carcinoma.
  • CNS was the only site of disease in 9 patients, 9 patients had CNS and abdominopelvic disease, and 4 also had concomitant extraperitoneal dissemination.
  • Following surgery, 17 received whole-brain radiotherapy and 5 received systemic chemotherapy.
  • Median survival from diagnosis of cerebral metastasis for the entire series was 16 months (range, 4-41 months).
  • Extracranial disease at the time of CNS metastasis and time interval between diagnosis of ovarian cancer and CNS involvement manifestation were the only factors significantly affecting survival.
  • CONCLUSIONS: Neurosurgical resection of brain metastasis from ovarian carcinoma is indicated in solitary lesions in the absence of systemic disease.
  • The role of chemotherapy and stereotactic radiosurgery should be investigated.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694664.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bondiau PY, Largillier R, Foa C, Rasendrarijao D, Frenay M, Gérard JP: [Treatment of brain metastasis from ovarian cancer]. Cancer Radiother; 2003 Jun;7(3):184-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of brain metastasis from ovarian cancer].
  • [Transliterated title] Traitement des métastases cérébrales du cancer de l'ovaire.
  • Systemic metastases from ovarian carcinoma are frequent, but they seldom affect the central nervous system.
  • We present here the case of a patient treated for an ovarian cancer by surgery and chemotherapy.
  • Three months after the end of chemotherapy, the patient developed cerebral metastases from ovarian carcinoma (CMOC) treated by iterative surgery and and whole brain irradiation.
  • As the frequency of solitary cerebral metastasis of ovarian cancer is higher than with other cancers, it is likely that they behave slightly differently.
  • CMOC can occur during or after adjuvant chemotherapy and the best management strategies to better define determinants of survival for patients are not well known.
  • It appears that a better outcome of CMOC may be obtained by an aggressive treatment, if possible, including surgery, radiotherapy, and chemotherapy.
  • Taking into account the increase in the incidence of the CMOC and their early occurrence, some authors have proposed a prophylactic brain radiotherapy in patients who receive adjuvant chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Cystadenoma, Serous / secondary. Cystadenoma, Serous / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Female. France / epidemiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Metrorrhagia / etiology. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12834774.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Yamagishi Y, Akiba Y, Izumiya M, Higuchi H, Iizuka H, Takaishi H, Nagata H, Hibi T: [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1167-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
  • Chemotherapies for recurrent gastric cancer have not yet been established.
  • Here we report a case of type 4 gastric cancer associated with lymphangitis carcinomatosis which became refractory to the previous chemotherapies.
  • She had been diagnosed with gastric cancer after a Krukenberg tumor operation.
  • Disease activity has been well controlled until this time.
  • Since recurrence of left pleural effusion and lymphangitis carcinomatosis was recognized, we changed the chemotherapy TS-1 plus CPT-11.
  • The serum CA 19-9 level rose transiently after CPT-11 administration, and tended to fall at the second week of chemotherapy.
  • TS-1 plus CPT-11 combination chemotherapy would be effective for lymphangitis carcinomatosis and also useful as third-line chemotherapy for recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Krukenberg Tumor / surgery. Lymphangitis / complications. Ovarian Neoplasms / surgery. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121922.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


35. Hasegawa H, Naitoh H, Tsuchihashi H, Okada K, Furukawa H, Hanasawa K: [A case of solitary splenic metastasis from an ovarian cancer 12 years after primary resection]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1799-803
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of solitary splenic metastasis from an ovarian cancer 12 years after primary resection].
  • A 57-year-old woman underwent total hysterectomy and bilateral salpingo-oophorectomy for bilateral ovarian tumors (T1b, N0, M0; Stage I b, serous cystoadenocarcinoma) in May 1994.
  • She received 4 courses of CAP (cyclophosphamide 500 mg/m2+epirubicin 50 mg/m2+cisplatin 60 mg/m2) therapy as adjuvant chemotherapy.
  • Since whole-body FDG-PET-CT showed no evidence of local recurrence of the ovarian cancer or multiple organ metastases, a solitary splenic metastasis from ovarian cancer, even though very rare, was strongly suspected.
  • Splenectomy with distal pancreatectomy was undertaken in December 2007.
  • Histopathological examination revealed poorly-differentiated adenocarcinoma, suggesting the final diagnosis of solitary splenic metastasis from ovarian cancer.
  • Periodic CA125 measurements are considered very important even over 10 years after surgery for ovarian cancer.
  • Once solitary splenic metastasis is diagnosed, surgical resection would be the treatment of choice.
  • [MeSH-major] Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20841951.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


36. Yano H, Iwazawa T, Kinuta M, Nakano Y, Tono T, Matsui S, Kanoh T, Monden T: Solitary splenic metastasis from ovarian cancer successfully treated by hand-assisted laparoscopic splenectomy: report of a case. Surg Today; 2002;32(8):750-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis from ovarian cancer successfully treated by hand-assisted laparoscopic splenectomy: report of a case.
  • Solitary splenic metastasis is an extremely rare phenomenon for which splenectomy is generally indicated because a good prognosis can be achieved if chemotherapy is given postoperatively.
  • We report herein a case of solitary splenic metastasis from ovarian cancer, which was completely removed by hand-assisted laparoscopic surgery.
  • [MeSH-major] Cystadenocarcinoma, Papillary / secondary. Laparoscopy / methods. Ovarian Neoplasms / pathology. Splenectomy / methods. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181732.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Chiu TJ, Chen YJ, Huang CH: Massive anterior chest wall metastasis of ovarian cancer and prolonged survival after treatment: a case report. J Reprod Med; 2008 May;53(5):373-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive anterior chest wall metastasis of ovarian cancer and prolonged survival after treatment: a case report.
  • BACKGROUND: Although previously uncommon, distant metastases of ovarian cancer are now observed with increasing frequency.
  • CASE: A 51-year-old woman presented with a massive metastatic tumor of the anterior chest wall 10 years after receiving total abdominal hysterectomy and bilateral salpingo-oophorectomy for primary ovarian cancer.
  • The extremely large size of the tumor precluded surgical resection.
  • Following successful chemotherapy and local irradiation, however, this patient has achieved long-term survival.
  • CONCLUSION: This report is the first to describe a case of a massive, inoperable chest wall tumor developing as a late metastasis of ovarian cancer.
  • Systemic chemotherapy combined with local irradiation represents effective treatment for such unusual cases.
  • [MeSH-major] Carcinoma, Papillary / secondary. Carcinoma, Papillary / therapy. Ovarian Neoplasms / pathology. Thoracic Neoplasms / secondary. Thoracic Neoplasms / therapy. Thoracic Wall

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567287.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Stippel DL, Kasper HU, Schleimer K, Töx U, Bangard C, Hölscher AH, Beckurts KT: Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc; 2005 Jun;37(5):2185-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation.
  • This 44-year-old woman developed multifocal hepatocellular carcinoma (HCC) within hepatitis B-induced liver cirrhosis.
  • At the time of listing for transplantation the HCC had progressed beyond the Milan criteria.
  • Due to her young age, high grade of histological differentiation according to biopsy, and lack of therapeutic alternatives, she was listed for transplantation.
  • Five months after transplantation bilateral bulky ovarian metastases were seen on computed tomography (CT) scan.
  • Fourteen months after this procedure and 19 months after transplantation, the patient is asymptomatic with stable liver function.
  • In conclusion, radical surgical treatment and immunosuppression using sirolimus may achieve tumor-free survival in selected patients with advanced or recurrent HCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Female. Hepatitis B / complications. Humans. Immunosuppressive Agents / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964374.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


39. Inoue Y, Toiyama Y, Yokoe T, Tanaka K, Miki C, Kusunoki M: Direct evidence that heterogeneity necessitates and limits the use of multidrug chemotherapy in colon cancer. Mol Med Rep; 2008 Jul-Aug;1(4):531-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct evidence that heterogeneity necessitates and limits the use of multidrug chemotherapy in colon cancer.
  • Considerable progress in the form of multidrug chemotherapy has recently been made in chemotherapy for the prolongation of survival in advanced colon cancer.
  • It is generally accepted that colon cancer is biologically heterogeneous for multiple properties, including sensitivity to chemotherapeutic agents and metastasis.
  • Although this partly explains the success of multidrug chemotherapy, there has been no direct evidence that multidrug regimens affect individual heterogenous cancer characteristics in colon cancer.
  • Here, we present a case of metachronous ovarian metastasis in a colon cancer patient with dissemination who underwent irinotecan-based followed by oxaliplatin-based chemotherapy.
  • We were able to obtain three samples from the patient, one of primary cancer and two of metastatic tumors from secondary surgery.
  • Of note, both chemoresistant and chemosensitive tumors were present in the patient at the same time.
  • To understand the influence of multidrugs on individual cancer characteristics, we examined differences in the molecular characteristics of the three samples using RT-PCR, focusing in particular on alterations in chemoresistant genes.
  • In shrunken peritoneal metastasis, we found a significant increase in the mRNA levels of an irinotecan-sensitive gene, although other molecular factors were resistant to both 5-FU and oxaliplatin.
  • We also confirmed that the recurrent ovarian tumor showed significant resistance to all three drugs: 5-FU, irinotecan and oxaliplatin.
  • These results suggest that the heterogeneity of colon cancer necessitates and limits the use of multidrug chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479445.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Giannakopoulos ChK, Kyriakidou GK, Toufexi GE: Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report. Eur J Gynaecol Oncol; 2005;26(3):339-41
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report.
  • Palmar fasciitis and a polyarthritis syndrome (PFPAS) is an uncommon paraneoplastic syndrome often associated with occult neoplasms, including ovarian and pancreatic carcinomas.
  • Twelve months after onset of the symptoms an ovarian and pancreatic adenocarcinoma was diagnosed synchronously.
  • The spread pattern and other features of the neoplasm indicate that it was a primary pancreatic cancer with ovarian metastasis.
  • Surgical excision of tumor and adjuvant chemotherapy caused remission of symptoms.
  • A literature review of PFPAS and secondary ovarian neoplasms with a pancreatic primary tumor is discussed.
  • [MeSH-major] Adenocarcinoma / secondary. Arthritis / etiology. Fasciitis / etiology. Ovarian Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Hand. Humans. Paraneoplastic Syndromes / etiology. Surgical Procedures, Operative. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991542.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


41. Cormio G, Di Vagno G, Di Fazio F, Loverro G, Selvaggi L: Intramedullary spinal cord metastasis from ovarian carcinoma. Gynecol Oncol; 2001 Jun;81(3):506-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary spinal cord metastasis from ovarian carcinoma.
  • BACKGROUND: Intramedullary spinal cord involvement by ovarian carcinoma is extremely rare.
  • CASE: A patient with stage IV serous cystadenocarcinoma of the ovary presented with neurologic complaints 16 months after primary treatment.
  • Magnetic resonance imaging demonstrated a metastatic lesion in the intramedullary area of the spinal cord.
  • No other site of metastatic disease was observed.
  • Following chemotherapy she was given radiotherapy on the spinal cord, but died 10 months later for disseminated abdominal disease, without neurologic symptoms.
  • CONCLUSION: Spinal cord involvement is unusual in ovarian carcinoma; multidisciplinary treatment, including chemotherapy and radiotherapy, may offer good palliation of the symptomatology.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11371147.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


42. Akhan SE, Işikoglu M, Salihoglu Y, Bengisu E, Berkman S: Brain metastasis of ovarian cancer after negative second-look laparotomy. Eur J Gynaecol Oncol; 2002;23(4):330-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of ovarian cancer after negative second-look laparotomy.
  • We present a case of ovarian carcinoma that had brain metastasis seven months after having a negative second-look laparotomy and 13 months after the onset of diagnosis.
  • Despite intense multidisciplinary treatment with surgery, chemotherapy and radiotherapy, the patient died seven months after second-look laparotomy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Laparoscopy. Magnetic Resonance Imaging. Middle Aged. Paclitaxel / administration & dosage. Second-Look Surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214736.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


43. Shimizu H, Taniguchi F, Sonoda H, Itokawa Y, Ikeda J, Yamashita T, Koide K, Ueshima Y, Takashina K, Lee CJ, Shioaki Y: [Two cases of advanced rectal cancer resected successfully after neoadjuvant chemotherapy with FOLFOX regimen]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2073-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced rectal cancer resected successfully after neoadjuvant chemotherapy with FOLFOX regimen].
  • We describe here two cases of locally advanced rectal cancer treated with neoadjuvant chemotherapy prior to surgery.
  • A detailed examination revealed a rectal cancer with direct invasion of the primary rectal carcinoma into the prostate.
  • Four courses of FOLFOX4 were administered as neoadjuvant chemotherapy.
  • The pathological examination revealed that all surgical margins were negative for malignancy and no metastasis to lymph nodes was found, therefore a surgical evaluation of curability was classified as A.
  • A detailed examination revealed a rectal cancer with metastasis to an ovary and paraaortic lymph node.
  • One course of FOLFOX4 and six courses of mFOLFOX6 (combined with bevacizumab in the first five courses) were administered as neoadjuvant chemotherapy.
  • Subsequent examinations revealed significantly reduced primary tumor and the size of metastatic lesion.
  • Given that metastasis to the paraaortic lymph node was difficult to determine, we performed a radical resection.
  • We determined that there was no residual cancer and evaluated the surgery as curability B.
  • We conclude that neoadjuvant chemotherapy against locally advanced rectal cancer may improve the curability of the surgery and save the surrounding organs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037327.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


44. Yang TS, Hsu KC, Tang R, Chang TC: Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases. Anticancer Drugs; 2000 Apr;11(4):279-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
  • Ovarian metastasis may present at the time of initial diagnosis of colon carcinoma or as a later recurrence.
  • Little meaningful information is available regarding the treatment and outcome of synchronous ovarian metastasis of colon carcinoma.
  • This report describes the clinical course of five patients with synchronous ovarian metastasis of colon carcinoma who were treated with aggressive surgery and chemotherapy.
  • The treatment consisted of maximal surgical debulking followed by systemic chemotherapy with weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin.
  • All of the five patients had subsequent disease-free periods ranging from 6 to 43+ months following operation.
  • Two of the patients who had no or minimal peritoneal involvement were still alive without disease at 33 and 43 months.
  • The data from these cases suggest that aggressive surgery and systemic chemotherapy may be highly efficacious in the treatment of colon carcinoma with synchronous ovarian metastasis.
  • Maximal debulking followed by chemotherapy may be particularly effective in those patients with minimal peritoneal involvement.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Colonic Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898544.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Yoshioka R, Okabayashi T, Nishimori I, Maeda N, Sugimoto T, Kohsaki T, Onishi S, Fukaya T, Kobayashi M, Hanazaki K: A long-survived case with solitary splenic metastasis from ovarian carcinoma. Surg Technol Int; 2008;17:192-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-survived case with solitary splenic metastasis from ovarian carcinoma.
  • A61-year-old postmenopausal woman with ovarian carcinoma was treated with two surgical operations and a series of platinum-based chemotherapy.
  • A solitary metastasis into the splenic parenchyma was identified 33 months after the second surgery by abdominal computed tomography with an increased serum level of CA-125.
  • She underwent a pancreaticosplenectomy and received platinum-based adjuvant chemotherapy continuously for 2 years.
  • Solitary metastases from ovarian cancer into the splenic parenchyma are extremely rare.
  • Among 18 cases previously reported, this present case shows the longest disease-free survival.
  • Because these cases show favorable prognosis after splenectomy, surgical treatment should be considered along with adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Ovarian Neoplasms / surgery. Splenectomy / methods. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802901.001).
  • [ISSN] 1090-3941
  • [Journal-full-title] Surgical technology international
  • [ISO-abbreviation] Surg Technol Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Furukawa N: Solitary splenic metastasis of ovarian cancer. Arch Gynecol Obstet; 2007 Jun;275(6):499-502
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis of ovarian cancer.
  • BACKGROUND: Solitary splenic metastasis occurs relatively rarely in ovarian cancer.
  • CASE REPORT: This report presents a patient in whom a solitary splenic metastasis was detected 9 years after diagnosis of stage Ic ovarian cancer.
  • The patient was a 59-year-old woman who was diagnosed with stage Ic ovarian serous cystadenocarcinoma in 1992, underwent postoperative chemotherapy, and exhibited no signs of recurrence in terms of clinical symptoms, markers and imaging findings.
  • Magnetic resonance imaging (MRI) suggested a malignant splenic tumor and CA125 levels were elevated at 485 U/ml.
  • The patient underwent a splenectomy and microscopy confirmed the splenic tumor to be of the same histological type as the ovarian cancer.
  • At present (60 months post splenectomy), the patient remains disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Splenectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096159.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


47. Mandai M, Konishi I, Tsuruta Y, Suginami N, Kusakari T, Iwasaki T, Fujii S: Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol; 2001 Jul;97(1):90-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature.
  • Appendiceal neoplasms with ovarian metastasis are rare.
  • A 35-year-old woman with a left ovarian tumor underwent left salpingo-oophorectomy, partial resection of the right ovary, and a total hysterectomy.
  • Pathological diagnosis of both ovaries was typical, Krukenberg tumor with signet-ring cells, and the second laparotomy revealed an occult appendiceal tumor to be the primary lesion.
  • The appendix showed no evidence of malignant change of the mucosa, but the tumor cells were observed infiltrating from the basiglandular region into the underlying stroma, associated with mucocele.
  • Although, argentaffin and argyrophil staining were negative, a few tumor cells showed immunohistochemical positivity for Chromogranin A.
  • Accordingly, the tumor was diagnosed as adenocarcinoid rather than adenocarcinoma of the appendix.
  • A review of the literature showed less than 40 cases of metastatic ovarian tumor from appendiceal primary, one-third of which were occult and could be detected at the second laparotomy.
  • Cisplatin-based chemotherapy may have partial effect in the treatment of patient with adenocarcinoid tumor.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A. Chromogranins / analysis. Cisplatin / therapeutic use. Fallopian Tubes / surgery. Fatal Outcome. Female. Humans. Hysterectomy. Immunohistochemistry. Intestinal Obstruction / etiology. Ovariectomy. Peritonitis / etiology

  • Genetic Alliance. consumer health - Adenocarcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11435017.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


48. mukai M, Moriya H, Himeno S, Oida Y, mukohyama S, Nishi T, Nakasaki H, Satoh S, Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases. Oncol Rep; 2001 Sep-Oct;8(5):1079-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases.
  • Case 1: a patient was diagnosed as having ascending colon cancer with right ovarian metastasis, and underwent palliative right hemicolectomy plus oophorectomy.
  • The tumor was a well-differentiated adenocarcinoma with right ovarian metastasis, and the disease was classified as stage IV.
  • Oral chemotherapy with UFT plus LV was performed for about 3 years, and the patient is still being followed up with no recurrence at 5 years postoperatively.
  • Case 2: a patient was diagnosed as having incomplete large bowel obstruction caused by ascending colon cancer, and underwent curative right hemicolectomy.
  • The tumor was a moderately differentiated adenocarcinoma, and the disease was classified as stage II.
  • Since multiple liver metastases developed at 3 months postoperatively, oral chemotherapy with UFT plus LV was started.
  • Subsequently, liver metastasis recurred about 10 months later.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Neoplasm Staging. Ovariectomy. Postoperative Period. Remission Induction. Tomography, X-Ray Computed


49. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol; 2009 Aug;33(8):1125-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
  • Risk-reducing salpingo-oophorectomy (RRSO) is an effective prophylactic procedure for women with mutations in BRCA1 or BRCA2 genes, both of which confer an increased lifetime risk for ovarian, tubal, peritoneal, and breast cancer.
  • In addition to lowering this risk, RRSO also offers the opportunity to detect occult early-stage fallopian tube or ovarian carcinoma.
  • The differential diagnosis of occult tubal/ovarian cancer includes a spectrum of benign tubal and ovarian alterations and also occult metastatic breast cancer, although only rare cases of the latter have been reported in RRSO.
  • Neoadjuvant breast cancer chemotherapy may contribute to diagnostic difficulty due to treatment-induced cytologic alterations.
  • With the aim of elucidating features which may help with differential diagnosis, this study reports the incidence and pathologic features of benign ovarian alterations, benign ovarian tumors, and occult primary and metastatic malignancies in prophylactic oophorectomies from 108 women with a BRCA mutation and from 35 women with other strong risk factors for hereditary breast/ovarian carcinoma.
  • We direct particular emphasis on morphologic features of primary ovarian lesions that may mimic occult metastatic breast cancer.
  • We also evaluate histologic alterations due to neoadjuvant breast cancer chemotherapy in the ovary and fallopian tube of patients who received such treatment immediately preceding RRSO.
  • Comparison is made to ovarian metastases of breast cancer in our hospital-based population of breast cancer patients, none of whom underwent RRSO.
  • Overall, 69% of RRSO patients had a personal history of breast cancer.
  • Neoadjuvant breast cancer chemotherapy was administered in 15%.
  • Occult primary carcinoma occurred in 7 (6.5%) BRCA patients (5 in fallopian tube, 1 in fallopian tube and ovary, 1 in ovary).
  • Ovarian metastasis of breast cancer occurred in 1 (1%) BRCA patient undergoing RRSO and in up to a similar proportion (0.8%) of the hospital-based population of breast cancer patients.
  • The metastasis in the RRSO patient was clinically occult, unilateral, 0.2 cm, and demonstrated mild atypia without mitoses.
  • Abundant foamy, vacuolated cytoplasm due to neoadjuvant chemotherapy exposure was notable.
  • In contrast, ovarian metastases in the non-RRSO population were all clinically detected, bilateral, large, and exhibited well-developed malignant cytologic features.
  • None of the normal cell types in the ovary or tube demonstrated any cytologic alterations in RRSO patients who received neoadjuvant chemotherapy.
  • The main morphologic mimics of metastasis with superimposed chemotherapy-induced alterations in RRSO were stromal hyperthecosis (n=8), nodular hyperthecosis (n=2), adrenal rests (n=3), hilus cell nodules (n=43), and hilus cell hyperplasia (n=4).
  • Occult primary ovarian carcinoma was reliably distinguished from ovarian metastases of breast cancer by WT-1+, p53+, mammaglobin-, GCDPF-immunoprofile.
  • These results demonstrate that evaluation of RRSO specimens requires awareness of a spectrum of ovarian lesions which may mimic occult primary or metastatic carcinoma; awareness of the masquerading effects of neoadjuvant chemotherapy; and awareness of the potential morphologic differences between occult metastatic breast cancer in RRSO and non-RRSO specimens.
  • [MeSH-major] Genes, BRCA1. Genes, BRCA2. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Humans. Mutation. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / prevention & control. Ovariectomy. Ovary / drug effects. Ovary / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440148.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Falchook GS, Wolff RA, Varadhachary GR: Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol; 2008 Mar;108(3):515-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases.
  • BACKGROUND: Ovarian metastases from pancreatic adenocarcinoma are uncommon and data on the clinical features, treatment, and survival of patients with pancreatic adenocarcinoma with ovarian metastases is limited.
  • The purpose of this study is to define the clinical characteristics and treatment strategies for this patient population.
  • METHODS: We reviewed the charts of 18 patients with pancreatic adenocarcinoma with ovarian metastasis who had presented to The University of Texas M. D.
  • Anderson Cancer Center from 1985 to 2005.
  • RESULTS: Of the 18 patients diagnosed with pancreatic adenocarcinoma and ovarian metastases, 8 (44%) presented with ovarian metastases initially and a pancreatic primary tumor became apparent only on further imaging or during surgery.
  • On pathology review, the primary pancreatic cancers (5 out of 18) and ovarian metastases (8 out of 16) showed mucinous characteristics.
  • Patients who underwent resection of their ovarian metastases followed by chemotherapy had a trend of longer median survival compared to patients who received chemotherapy alone without resection of the ovarian metastases (16.5 vs. 8.5 months, respectively; p=0.28).
  • Patients who responded to chemotherapy had a trend of longer survival compared to nonresponders (19 vs. 6 months, respectively; p=0.1).
  • No responses were observed in the ovarian metastases to chemotherapy alone.
  • CONCLUSIONS: Primary pancreatic adenocarcinoma with synchronous ovarian metastases may present initially as symptomatic ovarian masses and they commonly have mucinous histologic characteristics.
  • Surgical resection of ovarian metastases may play an important palliative role in the treatment of symptomatic patients with good performance status and lead to longer survival.
  • [MeSH-major] Adenocarcinoma / therapy. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Databases, Factual. Female. Humans. Medical Records. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Analysis. Texas. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Yu L, Li X, Yang W: Pulmonary blastoma metastatic to the ovary. Int J Gynecol Pathol; 2009 Jan;28(1):59-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary blastoma metastatic to the ovary.
  • A 38-year-old woman was diagnosed as biphasic PB (1 subgroup of sarcomatoid carcinoma) and treated by surgery, radiotherapy, and chemotherapy.
  • Six months later, the patient presented with menstrual disorder and a mass in the abdominal-pelvic cavity.
  • Abdominal hysterectomy and bilateral salpingo-oophorectomy showed the morphology of metastatic PB in both ovaries.
  • The metastatic tumor was composed exclusively of epithelial components resembling well-differentiated fetal adenocarcinoma.
  • To our knowledge, this is the first reported case of bilateral ovarian metastasis from biphasic PB.
  • [MeSH-major] Lung Neoplasms / pathology. Ovarian Neoplasms / secondary. Pulmonary Blastoma / secondary

  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jul;29(4):339-40 [20567146.001]
  • (PMID = 19047906.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Gold JS, Jaques DP, Bentrem DJ, Shah MA, Tang LH, Brennan MF, Coit DG: Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent. Ann Surg Oncol; 2007 Feb;14(2):365-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent.
  • BACKGROUND: Metastatic gastric cancer has a dismal prognosis.
  • We identified a subset of patients where surgical resection with therapeutic intent was undertaken in the setting of known metastatic disease.
  • METHODS: Review of a prospectively maintained database of gastric cancer patients at a single institution over a 19-year period was performed.
  • RESULTS: Thirty-seven patients with metastatic disease known prior to resection with therapeutic intent were identified out of 3384 patients with gastric cancer (1%).
  • Twelve patients had positive peritoneal cytology as the only evidence of metastasis, 21 had gross metastasis limited to peritoneal surfaces, one had peritoneal and ovarian metastasis, one had liver metastasis, one had retropancreatic lymph node metastasis, and one had a malignant pleural effusion.
  • Thirty-six patients (97%) received chemotherapy prior to resection, and 30 (81%) received postoperative chemotherapy.
  • The median time from diagnosis to resection was 4.5 months (range 1-22) in patients receiving preoperative chemotherapy.
  • Predictors of worse prognosis were cytologic or pathologic evidence of persistent metastatic disease at the time of resection or at laparoscopy within six weeks of resection (P < .01), N3 disease (P = .03), and total gastrectomy or additional organ resection (P = .04).
  • Metastatic disease as evidenced by cytology only was not associated with improved prognosis.
  • CONCLUSIONS: Highly selected patients with metastatic gastric cancer undergoing surgical resection with therapeutic intent have a relatively poor prognosis.
  • Persistent detectable metastatic disease after preoperative chemotherapy portends a particularly poor prognosis.
  • [MeSH-major] Stomach Neoplasms / secondary. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gastrectomy. Humans. Lymph Node Excision. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146744.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Vitaliani R, Spinazzi M, Del Mistro AR, Manara R, Tavolato B, Bonifati DM: Subacute onset of deafness and vertigo in a patient with leptomeningeal metastasis from ovarian cancer. Neurol Sci; 2009 Feb;30(1):65-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacute onset of deafness and vertigo in a patient with leptomeningeal metastasis from ovarian cancer.
  • Ovarian carcinoma is a common gynecological malignancy.
  • We describe the case of a 63-year-old woman diagnosed from an ovarian carcinoma with peritoneal seed, which was treated surgically and with chemotherapy.
  • Involvement of VIII cranial nerve as the presentation of leptomeningeal carcinomatosis in ovarian carcinoma is rare.
  • In the literature at least two other cases presented with deafness, suggesting that leptomeningeal carcinomatosis should be considered in the differential diagnosis when deafness appears in a cancer patient.
  • [MeSH-major] Carcinoma / secondary. Deafness / etiology. Meningeal Carcinomatosis / complications. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology. Vertigo / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellopontine Angle / pathology. Cerebellopontine Angle / physiopathology. Cerebrospinal Fluid / cytology. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Meninges / pathology. Middle Aged. Spinal Puncture. Tomography, X-Ray Computed. Vestibulocochlear Nerve / pathology. Vestibulocochlear Nerve / physiopathology


54. Bojalian MO, Machado GR, Swensen R, Reeves ME: Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review. Gynecol Oncol; 2004 May;93(2):557-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review.
  • BACKGROUND: Radiofrequency ablation (RFA) is a minimally invasive technique that can eradicate malignant disease in the liver, including metastatic disease from gynecological primary tumors.
  • CASE: An 81-year-old female underwent percutaneous RFA for a solitary intrahepatic metastatic lesion that was her only known site of disease 2 years after definitive surgery and chemotherapy for stage IIIC ovarian adenocarcinoma.
  • She was able to start systemic chemotherapy 1 week after RFA, and continues to be free of disease in the liver.
  • CONCLUSION: RFA can be a useful tool for treating liver tumors in patients who would otherwise not be candidates for liver resection.
  • Its advantages include minimal invasiveness, low morbidity, and rapid recovery for expeditious treatment with systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099981.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


55. Carlson NL, Krivak TC, Winter WE 3rd, Macri CI: Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign disease. Gynecol Oncol; 2002 Jun;85(3):529-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign disease.
  • CASE: This is the case of a 77-year-old gravida 2 para 2 who underwent exploratory laparotomy and surgical staging with optimal cytoreduction for Stage IIIC papillary serous ovarian carcinoma in February 1998.
  • After initial platinum-based chemotherapy, she presented with an enlarging nodule at the right upper quadrant laparoscopic port site.
  • Fine needle aspiration confirmed recurrent papillary serous ovarian carcinoma.
  • After a discussion of her options, she elected to undergo surgical resection with postoperative salvage chemotherapy.
  • CONCLUSION: Port site recurrences have been previously reported in patients who underwent initial surgical evaluation for ovarian carcinoma utilizing the laparoscopic approach.
  • However, it is unusual for recurrent cancer to appear in port sites or operative incisions not related to the initial cancer surgery.
  • [MeSH-major] Cystadenocarcinoma, Papillary / secondary. Laparoscopy / adverse effects. Neoplasm Seeding. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051886.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Minicozzi A, Borzellino G, Momo EN, Segattini C, Pitoni F, Steccanella F, De Manzoni G: [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up]. Ann Ital Chir; 2008 Jul-Aug;79(4):231-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
  • BACKGROUND: In order to treat the peritoneal carcinomatosis from abdominal neoplasms has been recently proposed complete peritonectomy associated with IntraPeritoneal Hyperthermic Chemotherapy (IHPC).
  • Primary tumor was ovarian carcinoma in ten patients: four cases presented peritoneal surface malignancies (PSM) after any time from hysteroadnexectomy related to primary tumor, six cases synchronous PSM.
  • Primary tumor was gastric cancer in seven patients: the peritoneal washing was positive in four cases and, during follow-up period after gastrectomy, other two cases presented PSM.
  • One patient was previously treated with ovariectomy for ovaric mass that resulted a Krukenberg's tumor of gastric cancer.
  • Primary tumor was pseudomixoma peritonei in four patients; cytoreductive surgery and IHPC was carried as first line therapy in only one patient.
  • Three patients were previously treated for colon carcinoma.
  • The drugs used were Mitomycin C (3.3 mg/m2/L) and Cisplatin (25 mg/m2/L).
  • RESULTS: The mean Peritoneal Cancer Index (PCI) was 14.
  • After a median follow-up of 8 months (range 2-34), 14 (58%) patients are alive and 13 are disease free.
  • CONCLUSIONS: Our experience is consistent with other studies for the high rate of postoperative morbidity associated with treatment, but we achieved best results on mortality and post-operative staying.
  • CRS associated with IHPC is a good therapeutic option especially in ovaric-related carcinosis and PMP.
  • It' s still debated whether it could be useful or not in colorectal related carcinosis, whereas there is a general agreement in the un uselessness of this technique in gastric cancer.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Peritoneum / surgery. Postoperative Complications. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093624.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Skírnisdóttir I, Garmo H, Holmberg L: Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol; 2007 Apr;105(1):166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.
  • OBJECTIVE: The aim of this register study was to determine occurrence of non-genital ovarian metastasis detected by gynecologic surgery presented as ovarian neoplasm in Sweden from 1 January 1990 to 31 December 2003.
  • Origin of metastases and time of detection in relation to surgery were recorded.
  • Age at diagnosis, survival for ovarian metastasis compared to ovarian cancer and prognostic factors were evaluated.
  • METHODS: Utilizing the population-based Swedish In-Patient Registry, Cancer Registry and Causes of Death Registry, we identified 255 cases with non-genital tract metastases to the ovaries detected at gynecological surgery.
  • During the study period, 10,955 newly diagnosed cases of ovarian cancer were reported to the Swedish Cancer Registry.
  • RESULTS: The proportion of ovarian metastases detected at surgery of all ovarian neoplasm increased from 1.7% to 3.0% during the study period.
  • The patients with ovarian metastasis of non-GI origin were younger than patients with primary ovarian cancer.
  • The most common primary diseases were breast cancer (29%), colon cancer (27%) and gastric cancer (16%).
  • Ovarian metastasis of GI origin preceded primary diagnosis in 51% of patients but for women with disease of non-GI origin the primary diagnosis was made in 18% of patients after surgery.
  • Five-year survival for patients with ovarian metastasis of GI origin was 11% and it was 24% if metastases were of non-GI origin.
  • Five-year survival for women with ovarian metastases from breast cancer was 26%.
  • In a multivariate analysis, GI surgery at primary surgery for ovarian metastasis was unfavorable prognostic factor.
  • Diagnosis of primary disease known before surgery, primary disease of non-GI or unknown origin and operation at university hospital all had favorable prognostic impact for overall survival.
  • CONCLUSIONS: Detection of non-genital ovarian metastasis at gynecologic surgery is associated with poor prognosis, and prognosis is worse in tumors with GI origin and if the primary is not detected prior to surgery.
  • The results indicate that a thorough patient evaluation is very important before surgery for suspected ovarian neoplasm.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Proportional Hazards Models. Registries. Survival Rate. Sweden / epidemiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gynecol Oncol. 2007 Jul;106(1):276
  • (PMID = 17184826.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Moshfeghi DM, Wilson MW, Haik BG, Hill DA, Rodriguez-Galindo C, Pratt CB: Retinoblastoma metastatic to the ovary in a patient with Waardenburg syndrome. Am J Ophthalmol; 2002 May;133(5):716-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma metastatic to the ovary in a patient with Waardenburg syndrome.
  • PURPOSE: To report a child with retinoblastoma and Waardenburg syndrome who developed ovarian metastases.
  • The patient had a Reese-Ellsworth Group Va tumor and underwent enucleation.
  • Two years later, she developed metastatic disease involving the bone marrow, right humerus, both supraorbital bones, and both tibias.
  • She was treated with chemotherapy, orbital irradiation, and bone marrow transplant but returned 7 months later with back pain and urinary retention.
  • RESULTS: Exploratory laparotomy revealed a right ovarian mass, and the excised ovary showed metastatic retinoblastoma.
  • The child underwent chemotherapy and remained asymptomatic for 9 months, when brain metastases were diagnosed.
  • CONCLUSION: We believe that this is the first description of a patient with retinoblastoma and Waardenburg syndrome and of an ovarian metastasis from retinoblastoma.
  • [MeSH-major] Ovarian Neoplasms / secondary. Retinal Neoplasms / pathology. Retinoblastoma / secondary. Waardenburg Syndrome / pathology
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Child, Preschool. Eye Enucleation. Fatal Outcome. Female. Humans. Ovariectomy

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Genetic Alliance. consumer health - Waardenburg syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11992879.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / P30-CA23099
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


59. Takagi T, Nakase Y, Fukumoto K, Miyagaki T, Yamakawa N, Taniike K, Kobayashi Y, Kanemitsu D, Kassai K, Sakamoto K, Takenaka S, Itani K: [A patient with metachronous ovarian metastases of signet-ring cell carcinoma of the transverse colon showing long-term survival after surgery]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2260-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with metachronous ovarian metastases of signet-ring cell carcinoma of the transverse colon showing long-term survival after surgery].
  • She was referred to our hospital for close evaluation and treatment.
  • Since circumferential cancer was detected in the transverse colon by lower digestive tract endoscopy, the patient was hospitalized for surgical treatment.
  • Transverse colectomy (Cur A) was performed, histopathological examination indicated signet-ring cell carcinoma of the transverse colon, and the lesion was diagnosed as type 4, SS, ly3, v0, n1 (+), Stage III a.
  • Postoperative adjuvant chemotherapy was recommended, but the patient was psychologically unstable and strongly rejected chemotherapy.
  • The patient was periodically followed-up after surgery, but a mass was detected in the left ovary by CT after 1 year and 6 months, and bilateral ovariectomy was performed with a diagnosis of ovarian metastasis.
  • The histopathological diagnosis was signet-ring cell carcinoma, and the ovarian lesions were judged to be metastases of the transverse colon carcinoma.
  • Since the patient did not consent to postoperative chemotherapy, as after the initial surgery, she was followed-up without treatment.
  • She was admitted with ileus due to peritoneal metastasis 4 years and 10 months after the initial surgery, and, despite of the surgery, she died due to carcinoma 5 years after the initial surgery.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Colon, Transverse. Colonic Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / secondary. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037389.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Xu L, Zhan YQ: [Clinical analysis of 55 ovarian metastatic tumors from digestive system]. Ai Zheng; 2002 Mar;21(3):311-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 55 ovarian metastatic tumors from digestive system].
  • BACKGROUND & OBJECTIVES: Ovarian metastasis of digestive system tumors is a special way of tumor metastasis, which the diagnosis and treatment are difficult.
  • The objective of this paper is to seek the clinical characteristics of ovarian metastatic tumors from digestive system, to aid correct diagnosis and treatment, so that to improve their curative effect.
  • METHODS: The authors collected the information of 55 patients with ovarian metastatic tumors from digestive system, and analyzed 12 items of the patients including their age, menorrhea and child-bearing, details of original tumors and metastatic tumors, pathologic types, ascites, clinical symptoms, tumor markers, time of metastasis, diagnosis, treatment, curative effect, etc.
  • CONCLUSION: Ovarian metastatic tumors from digestive system are easy to be misdiagnosed, and have poor prognosis.
  • Careful long-term follow-up and active operation and chemotherapy may be effective to improve their curative effect.
  • [MeSH-major] Diagnostic Errors. Digestive System Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12452002.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Rafii A, Ferron G, Lacroix-Triki M, Dalenc F, Gladieff L, Querleu D: Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:334-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature.
  • Occurrence of parietal metastases after surgery for a suspect adnexal mass may worsen the prognosis of the disease.
  • However, it is not clear whether abdominal wall metastases is related to specific biologic features or simply to surgical mismanagement involving small incisions and traumatic extraction of the specimen, resulting in direct seeding of cancer cells.
  • We report two cases with development of parietal dissemination of ovarian carcinomas after Pfannenstiel incision.
  • Pfannenstiel incisions for exploration of suspicious adnexal masses increase the risk of extensive parietal metastasis in case of malignancy because they require reflection of several sheaths of tissue.
  • The parietal extension of the disease may need major parietal resection that can worsen the functional and general outcome of the patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Granulosa Cell Tumor / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Abdominal Wall. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515617.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol
  •  go-up   go-down


62. Zhang MQ, Chen MZ: [Analysis of 174 cases with cervical cancer in women under 35 years old]. Zhonghua Fu Chan Ke Za Zhi; 2003 Nov;38(11):689-93
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 174 cases with cervical cancer in women under 35 years old].
  • OBJECTIVE: To analyse the prevalence, etiology, presentation, preserving ovary and prognosis of cervical cancer in women under 35 years old.
  • RESULTS: The percentage of new cervical cancer cases from 1991 to 2001 was 1.2%, 1.2%, 4.3%, 4.2%, 4.6%, 4.5%, 7.3%, 9.0%, 10.7%, 9.4%, 10.8%, respectively (P < 0.01).
  • The number of cases with carcinoma in situ, stage I, stage II, stage III was 22, 40, 94, 18, respectively.
  • The ovarian metastasis was 0.8%.
  • COX regression analysis indicated that stage, lymph-vascular involvement and the depth of tumor infiltration were independently prognostic factors.
  • For patients with one risk factor after radical surgery, the survival of patients with adjuvant radiation therapy and chemotherapy or not was 100%, 88%, respectively (P > 0.05).
  • CONCLUSIONS: There is an increasing prevalence of cervical cancer in women under 35 years old, which is possibly related to the sexual transition.
  • The preserving ovary in young cervical cancer patients is safe and effective.
  • Adjuvant treatment may be helpful for patients with 2 or more risk factors after radical surgery.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728859.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Zanetta G, Gabriele A, Vecchione F, Landoni F, Isimbaldi G: Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. Gynecol Oncol; 2000 Mar;76(3):409-12
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery.
  • The use of less radical procedures for the treatment of early cervical cancers is gaining interest among physicians and young patients.
  • After a polypectomy, a young patient had a diagnosis of stage Ia(2) cervical adenosquamous carcinoma in 1995.
  • As she wished to preserve her fertility, she underwent a cone biopsy and pelvic lymphadenectomy, without evidence of tumor spread.
  • In 1998, at the 13th week of gestation, she had a diagnosis of a pelvic mass.
  • The mass was a recurrence of carcinoma involving the myometrium, just underneath the peritoneum.
  • An ovarian metastasis was also detected at pathological exam.
  • She received chemotherapy postoperatively and remains alive without evidence of disease.
  • The recurrence of cervical cancer is traditionally regarded as an issue concerning the cervix, the parametria, or the lymph nodes.
  • With wider acceptance of limited therapeutic approaches we must be prepared for the detection of previously unknown patterns of recurrence and the follow-up modalities must be consequently adapted.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Conization. Female. Humans. Lymph Node Excision. Neoplasm Invasiveness. Pregnancy. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10684719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


64. Kawakubo N, Okido M, Tanaka R, Mitsugi K, Fukuhara M, Aishima S, Kato M, Ichimiya H: Pseudo-Meigs' syndrome associated with breast cancer metastasis to both ovaries: Report of a case. Surg Today; 2010 Dec;40(12):1148-51
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meigs' syndrome associated with breast cancer metastasis to both ovaries: Report of a case.
  • A 50-year-old woman was admitted because of abdominal fullness due to bilateral ovarian tumors, pleural effusion, and ascites associated with breast cancer.
  • Although chemotherapy and the removal of ascites were performed periodically, the ascites did not disappear.
  • Pseudo-Meigs' syndrome caused by metastasis to both ovarian tumors was suspected.
  • The patient underwent a bilateral salpingo-oophorectomy, and the pathological diagnosis was bilateral metastatic ovarian tumors from breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Meigs Syndrome / etiology. Meigs Syndrome / surgery. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Quality of Life

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1954 May;3(5):471-86 [13154792.001]
  • [Cites] Breast Cancer. 2006;13(4):344-8 [17146160.001]
  • [Cites] Dig Surg. 2000;17(4):418-9 [11053957.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):248-51 [15047245.001]
  • [Cites] J R Soc Med. 1987 Apr;80(4):252-3 [3585894.001]
  • [Cites] Surg Today. 2003;33(5):387-91 [12734738.001]
  • [Cites] Obstet Gynecol. 2002 May;99(5 Pt 2):917-9 [11975958.001]
  • (PMID = 21110158.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Gupta D, Deavers MT, Silva EG, Malpica A: Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol; 2004 Jun;28(6):771-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
  • Ovarian malignant melanoma (MM), primary or metastatic, is an extremely rare tumor and in the absence of a previous diagnosis can represent a diagnostic challenge.
  • A previous history of MM was definitively obtained in 14 patients; in these cases, the interval between the primary MM and the ovarian metastasis ranged from 15 to 228 months (mean 77.7 months).
  • The tumor was unilateral in 19 and bilateral in 4 cases.
  • The tumor size ranged from 4.5 to 23 cm (average 10 cm); the melanoma arising in a cystic teratoma was 0.2 mm in thickness.
  • The tumor was grossly pigmented in 8 cases (35%).
  • The tumor cell type was epithelioid in 19 cases, spindled in 2 cases, mixed epithelioid and spindled in 1 case, and small cell in 1 case.
  • In 8 cases, initial diagnoses included sex cord stromal tumor, germ cell tumor, sarcoma, or undifferentiated carcinoma.
  • Treatment performed in 18 of the cases are as follows: oophorectomy with/without chemotherapy (10); total abdominal hysterectomy with bilateral salpingo-oophorectomy with/without chemotherapy (6); vaginal hysterectomy, bilateral salpingo-oophorectomy, and chemotherapy (1); and total abdominal hysterectomy with salpingo-oophorectomy (1).
  • Follow-up ranging from 2 to 96 months was available in 18 patients.
  • Thirteen patients died of disease (range 2-76 months), 3 are alive with disease (6-18 months), and 2 have no evidence of disease at 24 and 96 months; one was the patient with melanoma arising within a teratoma.
  • In conclusion, MM involving the ovary is a rare disease, predominantly seen in women of reproductive age, and is associated with a poor prognosis.
  • The tumor is most often metastatic from another site and is unilateral in most cases.
  • Nodular or diffuse pattern and epithelioid cell type are most frequently seen, and the tumor can be mistaken for germ cell and sex cord stromal tumors.
  • [MeSH-major] Melanoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Calbindin 2. DNA-Binding Proteins / analysis. Ethnic Groups. Female. Humans. Hysterectomy. Immunohistochemistry. Inhibins / analysis. MART-1 Antigen. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor. Middle Aged. Monophenol Monooxygenase / analysis. Neoplasm Metastasis. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. S100 Proteins / analysis. Teratoma / pathology. Transcription Factors / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15166669.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA-Binding Proteins; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Transcription Factors; 57285-09-3 / Inhibins; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


66. Sandmeier D, Lobrinus JA, Vial Y, Delaloye JF, Genton CY: Bilateral Krukenberg tumor of the ovary during pregnancy. Eur J Gynaecol Oncol; 2000;21(1):58-60
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Krukenberg tumor of the ovary during pregnancy.
  • Large bilateral ovarian tumors were observed which were interpreted as pregnancy luteomas.
  • Nevertheless a biopsy of the right ovary was performed.
  • Histologic examination revealed massive luteinization of the ovarian stroma.
  • In addition, large tumor cells were found dispersed throughout the ovary as well as in vascular spaces as either isolated or clustered signet-ring cells.
  • In search of the primary tumor, gastroscopy revealed a gastric ulcer in the antrum.
  • The biopsies of the ulcer margins as well as those taken at distance demonstrated signet-ring cells in the lamina propria.
  • In spite of postoperative chemotherapy, the patient died of disease 5 months after diagnosis.
  • [MeSH-major] Krukenberg Tumor / secondary. Luteoma / pathology. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10726620.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


67. Ren J, Li Y, Zhang YL, Zhou XH, Zhang L, Yang Y, Li Y: [Effect of inhibitors of phospholipase A(2); on the metastasis potentials of human ovarian cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Oct;26(10):992-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of inhibitors of phospholipase A(2); on the metastasis potentials of human ovarian cancer cells].
  • AIM: it is important to find inhibitors for metastasis of ovarian cancer (OC).
  • This study is to investigate the effect of PLA(2); inhibitors on the metastasis of OC.
  • METHODS: cell migration and adhesion were measured by Transwell assay.
  • Metastasis was detected through in vivo OC model. RESULTS:.
  • (2) iPLA(2); and cPLA(2); expressed highly and activated in SKOV3. (3)AACOCF3 and HELSS significantly inhibited LPA secretion from SKOV3; (4)AACOCF3 and HELSS significantly inhibited the distant metastasis of SKOV3 in mude mice model.
  • They also inhibited the distant metastasis of SKOV3 in vivo.
  • Our data suggest AACOCF3 and HELSS may be the potential inhibitors of metastasis of OC.
  • [MeSH-major] Lysophospholipids / therapeutic use. Neoplasm Metastasis / drug therapy. Ovarian Neoplasms / drug therapy. Phospholipases A / antagonists & inhibitors
  • [MeSH-minor] Animals. Blotting, Western. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20937237.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lysophospholipids; EC 3.1.1.- / Phospholipases A
  •  go-up   go-down


68. Chudy B, Łata S: [49 year old patient with staphylococcal sepsis caused by agranulocytosis after polychemotheraphy]. Przegl Lek; 2010;67(5):440-1
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents a case of adverse effects of chemotherapeutic agents: alkylating drug (cisplatyna) and taksoin (taxol) on a patient with metastatic cancer of unknown primary which was manifesting with Krukenberg tumor symptoms.
  • The main disease symptoms were caused by bone marrow malignant infiltrations, and pancytopenia in peripheral blood, but mainly staphylococcal sepsis and hemorrhagic diathesis.
  • In conclusion, the need to be cautious while making the decision to implement chemotherapy on patients with very advanced cancer in terms of prolonging their lives was pointed out.
  • [MeSH-major] Agranulocytosis / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy. Sepsis / etiology. Staphylococcal Infections / etiology
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Humans. Krukenberg Tumor / diagnosis. Krukenberg Tumor / drug therapy. Krukenberg Tumor / secondary. Middle Aged. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Sepsis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684357.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Neverauskiene S, Machtejeviene E, Vaitkiene D, Juodzbaliene EB: [Disseminated ovarian, bone, and bone marrow metastases from gastric cancer]. Medicina (Kaunas); 2006;42(11):923-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated ovarian, bone, and bone marrow metastases from gastric cancer].
  • The main cause of death in patients with gastric cancer is disease dissemination.
  • It is not clear why gastric cancer metastasizes to different organs.
  • Early detection and destruction of circulating malignant cells before developing metastases may markedly improve survival of these patients.
  • Krukenberg tumors (metastases of non-gynecological origin in the ovaries) usually are circular cell carcinomas of gastric cancer.
  • Bone metastases of gastric cancer are rare, but if they are diagnosed, patients survive only 2-5 months on the average.
  • Disseminated bone marrow metastases from gastric cancer do not always show the sudden course of the disease, but hematological complications are signs of poor prognosis.
  • Currently, chemotherapy is the most effective treatment for outspread gastric cancer.
  • Unfortunately, there is no exclusively effective scheme for treatment.
  • Lymph node metastases are more sensitive to chemotherapy than primary gastric cancer, while in contrary, hepatic metastases are less sensitive than primary gastric cancer.
  • This article includes a literature review and a rare case of gastric cancer.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Carcinoma / secondary. Ovarian Neoplasms / secondary. Paraneoplastic Syndromes. Stomach Neoplasms
  • [MeSH-minor] Biopsy. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Stomach / pathology. Time Factors


70. Sugiyama T, Sadzuka Y: Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim Biophys Acta; 2003 Dec 5;1653(2):47-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biochemical modulation has played an important role in the development of cancer chemotherapy.
  • In M5076 ovarian sarcoma-bearing mice, theanine significantly enhanced the inhibitory effect of DOX on tumor growth and increased the DOX concentration in the tumor, compared to DOX-alone group.
  • Moreover, the combination of theanine with DOX suppressed the hepatic metastasis of ovarian sarcoma.
  • In contrast, an increase in DOX concentration was not observed in normal tissues, such as liver and heart.
  • On the other hand, in vitro experiments proved that theanine inhibited the efflux of DOX from tumor cells, supporting a theanine-induced increase in the DOX concentration in tumors in vivo.
  • The reduction in the concentration of glutamate in tumor cells caused by theanine induced decreases in the intracellular glutathione (GSH) and GS-DOX conjugate levels.
  • Namely, theanine increases the concentration of DOX in a tumor in vivo through inhibition of the glutamate transporter via the GS-X pump.
  • Consequently, the modulating effect of theanine on the efficacy of antitumor agents is expected to be applicable in clinical cancer chemotherapy.
  • [MeSH-major] Amino Acid Transport System X-AG / antagonists & inhibitors. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Glutamates / pharmacology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Drug Synergism. Enzyme Inhibitors / pharmacology. Humans. Mice

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Theanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14643924.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acid Transport System X-AG; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Glutamates; 80168379AG / Doxorubicin; 8021PR16QO / theanine
  • [Number-of-references] 66
  •  go-up   go-down


71. Gadducci A, Tana R, Teti G, Fanucchi A, Pasqualetti F, Cionini L, Genazzani AR: Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res; 2007 Nov-Dec;27(6C):4403-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
  • The aim of the investigation was to assess 12 cases of brain recurrences among ovarian cancer patients who had undergone surgery followed by platinum-based chemotherapy.
  • The median time from ovarian cancer diagnosis to brain metastasis detection was 33.5 months (range, 13.5-86.5 months), brain metastases were multiple in 6 (50%) cases, and extra-cranial disease was present in 7 (58%) cases.
  • Out of the 6 patients with single brain metastases, one underwent surgery, one had surgical excision followed by whole brain irradiation, 3 patients received stereotactic radiotherapy (followed by chemotherapy for coexistent extra-abdominal recurrence in one), and one had only symptomatic treatment.
  • Out of the 6 patients with multiple brain metastases, four received whole brain irradiation (followed by chemotherapy for concomitant extra-cranial recurrence in one case), one patient had gamma-knife irradiation of three cerebral lesions (followed by chemotherapy for concurrent abdominal recurrence), and one patient had only symptomatic treatment.
  • The median overall survival from diagnosis of brain metastasis was 8.3 months (range, 1-28 months), and it was not related to the number of brain metastases (multiple versus single), presence or absence of extra-cranial disease, or interval between ovarian cancer diagnosis and brain metastasis detection (<33.5 months versus > or =33.5 months).
  • In conclusion, brain metastasis from ovarian cancer can represent a late manifestation of the disease, associated with a very poor prognosis.
  • [MeSH-major] Brain Neoplasms / secondary. Ovarian Neoplasms / pathology


72. Kaji M, Kabir-Salmani M, Anzai N, Jin CJ, Akimoto Y, Horita A, Sakamoto A, Kanai Y, Sakurai H, Iwashita M: Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer; 2010 Apr;20(3):329-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
  • HYPOTHESIS: To investigate the expression and the functional properties of L-type amino acid transporter 1 (LAT1) in human epithelial ovarian cancer to provide a basis for potential new therapies to control the growth and the metastasis of ovarian cancer.
  • The expression of LAT1 in 53 cases of ovarian cancers was determined by Western blot and immunohistochemical staining, and results were compared with those of normal ovarian tissues (5 cases) and benign ovarian tumors (5 cases).
  • Furthermore, we examined the effect of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), the classic inhibitor of system L on the survival, the migration, and the uptake of l-leucine by human epithelial ovarian cancer cell line (OVCAR-3).
  • RESULTS: The LAT1 was significantly up-regulated in various human epithelial ovarian cancers that was localized predominantly on their plasma membrane and in the plasma membrane of the ovarian cancer cell line in conjunction with 4F2hc via disulfide bonds.
  • CONCLUSIONS: The LAT1 plays significant roles in nutrition, proliferation, and migration of ovarian cancer.
  • Then, LAT1 inhibition would be useful for anticancer therapy in suppressing tumor growth without affecting normal tissues.
  • [MeSH-major] Large Neutral Amino Acid-Transporter 1 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Amino Acids, Cyclic / pharmacology. Blotting, Western. Cell Adhesion / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Female. Fluorescent Antibody Technique. Humans. Immunoenzyme Techniques. Leucine / metabolism. Ovary / drug effects. Ovary / metabolism. Ovary / pathology. Peptide Fragments / immunology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375792.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Cyclic; 0 / Large Neutral Amino Acid-Transporter 1; 0 / Peptide Fragments; 20448-79-7 / 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid; GMW67QNF9C / Leucine
  •  go-up   go-down


73. Taylor J, Amanze A, Di Federico E, Verschraegen C: Irinotecan use during pregnancy. Obstet Gynecol; 2009 Aug;114(2 Pt 2):451-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ovarian tumors during pregnancy are rare.
  • There is sparse clinical evidence about the safety of chemotherapy in this situation.
  • CASE: A 34-year-old woman was diagnosed by ultrasonography at 15 1/2 weeks of pregnancy with a Krukenberg tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Krukenberg Tumor / therapy. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / therapy. Prenatal Care

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Prenatal Care.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622957.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


74. Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, Wang WJ: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl); 2008 Aug 5;121(15):1394-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis.
  • Ginsenoside Rg3 has been found to inhibit several kinds of tumor growth and metastasis.
  • The present study was undertaken to investigate the effect of ginsenoside Rg3 on human ovarian cancer metastasis and the possible mechanism.
  • METHODS: The experimental lung metastasis models of ovarian cancer SKOV-3 and the assay of tumor-induced angiogenesis were used to observe the inhibitory effects of Rg3 on tumor metastasis and angiogenesis.
  • RESULTS: In the experimental lung metastasis models of ovarian cancer, the number of tumor colonies in the lung and vessels oriented toward the tumor mass in each ginsenoside Rg3 group, was lower than that of control group.
  • The invasive ability and MMP-9 expression of SKOV-3 cells decreased significantly after treatment with ginsenoside Rg3.
  • CONCLUSIONS: Ginsenoside Rg3 can significantly inhibit the metastasis of ovarian cancer.
  • The inhibitory effect is partially due to inhibition of tumor-induced angiogenesis and decrease of invasive ability and MMP-9 expression of SKOV-3 cells.
  • [MeSH-major] Ginsenosides / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Matrix Metalloproteinase 9 / metabolism. Mice. Neoplasm Invasiveness. Neovascularization, Pathologic / prevention & control

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959116.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ginsenosides; 14197-60-5 / ginsenoside Rg3; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


75. Wong FC, Pang CP, Tang SK, Tung SY, Leung TW, Sze WK, Cheung KB: Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement. Clin Oncol (R Coll Radiol); 2004 Aug;16(5):350-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement.
  • AIMS: To review the treatment results of patients with endometrial carcinoma having positive peritoneal washing (PPW), adnexal involvement, uterine serosal involvement, or all three.
  • MATERIALS AND METHODS: The treatment records of patients who had undergone primary surgery for endometrial cancer without distant metastasis during 1990--2001 at the Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, were reviewed.
  • Seven (20%) of them had gross or microscopic lymph-node metastasis.
  • Two patients with solitary ovarian metastasis received chemotherapy, and one with isolated PPW also received adjuvant hormonal therapy.
  • RESULTS: Among the 28 patients with clinical or pathological node-negative disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIA), only two patients with solitary ovarian metastases developed recurrence.
  • The 5-year actuarial disease-free survival (DFS) rates for the whole group and patients without lymph-node involvement were 77.9% and 91.7%, respectively.
  • Five out of the seven patients with lymph-node involvement developed recurrences.
  • Univariate analysis showed that lymph-node involvement (P < 0.0001) and high-grade disease (P = 0.011) were the significant poor prognostic factors.
  • Only one patient (3.7%) who had received WART developed grade 4 toxicity.
  • CONCLUSIONS: This study showed that good treatment results could be obtained from patients with stage IIIA endometrial carcinoma without clinical or pathological lymph-node involvement after adjuvant radiotherapy, with acceptable late side-effects.
  • The relative prognostic importance of individual IIIA involvement and the optimal adjuvant treatment remain to be determined.
  • [MeSH-major] Ascitic Fluid / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Myometrium / pathology. Neoplasm Staging. Ovary / pathology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Review Literature as Topic. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15341439.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Yamazawa K, Matsui H, Ishikura H, Seki K, Mitsuhashi A, Sekiya S: Significance of perivascular lymphocytic infiltrates on survival of patients with invasive cervical cancer. J Immunother; 2003 Mar-Apr;26(2):149-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of perivascular lymphocytic infiltrates on survival of patients with invasive cervical cancer.
  • The authors retrospectively reviewed the medical records of 129 patients with stage IB and II cervical cancer (93 squamous cell carcinomas, 30 adenocarcinomas, and 6 adenosquamous carcinomas) who underwent primary surgery between 1989 and 2000.
  • Vascular invasion is the predictor of recurrence, and lymphocytic infiltrates within the tumor is associated with favorable outcome in cervical cancer.
  • Age, clinical stage, histology, tumor grade, depth of stromal invasion, VI and PLI, tumor size, ovarian metastasis, pelvic lymph node metastasis, postoperative irradiation, and chemotherapy were assessed statistically for recurrence of the disease by Cox regression analysis.
  • Disease-free survival was analyzed using Kaplan-Meier survival analysis.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biopsy, Needle. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Hysterectomy / methods. Immunohistochemistry. Japan. Lymph Node Excision. Middle Aged. Multivariate Analysis. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis


77. Hornung M, Vogel P, Schubert T, Schlitt HJ, Bolder U: A case of virilization induced by a Krukenberg tumor from gastric cancer. World J Surg Oncol; 2008;6:19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of virilization induced by a Krukenberg tumor from gastric cancer.
  • BACKGROUND: The Krukenberg tumor represents ovarian metastases associated with gastric cancer or other gastrointestinal malignancies.
  • Histology shows typical mucus-production and numerous signet-ring cells.
  • Occasionally Krukenberg tumors have endocrine function and, as a consequence, some patients demonstrate hirsutism and virilization.
  • CASE PRESENTATION: Here we report a case of virilization associated with an extensive gastric adenocarcinoma and Krukenberg tumor in a premenopausal woman.
  • Virilization occurred three months after diagnosis of gastric cancer and the ovarian tumors.
  • Palliative chemotherapy was initiated as primary therapy, but gastric outlet obstruction required a gastrojejunostomy.
  • In addition, oopherectomy was performed to relieve abdominal tension and to abate hormonal effects.
  • CONCLUSION: Despite the limitation in survival time early oopherectomy should be considered to prevent the development of virilization even in palliative situations if a Krukenberg tumor is diagnosed with gastric cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell / therapy. Krukenberg Tumor / therapy. Ovarian Neoplasms / therapy. Virilism / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fatal Outcome. Female. Gastric Bypass. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / surgery. Humans. Ovariectomy. Palliative Care. Premenopause. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1982 Oct;14(1):49-53 [6290279.001]
  • [Cites] J Gastroenterol. 2003;38(12):1176-80 [14714257.001]
  • [Cites] Lancet. 1977 May 28;1(8022):1162-3 [68266.001]
  • [Cites] Am J Obstet Gynecol. 1973 Oct 15;117(4):575 [4591259.001]
  • [Cites] Obstet Gynecol. 1968 Aug;32(2):221-5 [4316071.001]
  • [Cites] Am J Obstet Gynecol. 1968 Apr 15;100(8):1062-70 [5643184.001]
  • [Cites] J Clin Endocrinol Metab. 1968 Feb;28(2):198-214 [4295131.001]
  • [Cites] Am J Surg Pathol. 2006 Mar;30(3):277-99 [16538048.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):105-9 [11426970.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Am J Obstet Gynecol. 1965 Jul 1;92:702-10 [14308742.001]
  • [Cites] Zentralbl Gynakol. 1950;72(5):300-9 [15413399.001]
  • [Cites] Am J Obstet Gynecol. 1965 Aug 1;92:981-91 [14321115.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(1):61-5 [10394095.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1997;26(8):831-3 [9509327.001]
  • [Cites] Eur J Gynaecol Oncol. 1995;16(1):59-64 [7744119.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):81-4 [1851127.001]
  • [Cites] Obstet Gynecol. 1988 Mar;71(3 Pt 2):432-4 [2831488.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Aug;47(2):428-34 [263306.001]
  • [Cites] Minerva Ginecol. 1977 Nov;29(11):910-5 [204886.001]
  • (PMID = 18279511.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2275731
  •  go-up   go-down


78. Cosme A, Ojeda E, Bujanda L, Torrado J, Barrio J: [Krukenberg tumor secondary to gastric carcinoma in a woman in her eighth month of pregnancy]. Gastroenterol Hepatol; 2001 Feb;24(2):63-5
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Krukenberg tumor secondary to gastric carcinoma in a woman in her eighth month of pregnancy].
  • [Transliterated title] Tumor de Krukenberg secundario a carcinoma gástrico en una gestante de ocho meses.
  • The association of gastric cancer and pregnancy is rare.
  • Tumors tend to be in advanced stage when diagnosed since the symptoms of gastric cancer are easily presumed to be secondary to those of normal pregnancy.
  • We report the case of a 43-year-old female with gastric carcinoma presenting as a Krukenberg's tumor in the eighth month of gestation.
  • A healthy child was born and after delivery, partial gastrectomy was performed and adjuvant chemotherapy was administered.
  • The patient died 12 months after diagnosis.
  • [MeSH-major] Krukenberg Tumor. Ovarian Neoplasms. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Krukenberg carcinoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11247291.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E: Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol; 2008 Jan;108(1):248-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.
  • BACKGROUND: Dissemination of ovarian cancer occurs mainly within the peritoneal cavity and central nervous system involvement (CNS) is encountered rarely.
  • This report describes an unusual case with iatrogenic leptomeningeal metastasis from ovarian carcinoma.
  • CASE: 36 year-old lady diagnosed with ovarian carcinoma develops neurologic symptoms 10 months following primary treatment.
  • She undergoes surgery for obstruction of the VP catheter and pathologic evaluation reveals metastatic carcinoma consistent with the primary diagnosis.
  • With subsequent systemic chemotherapy, the patient remains alive for 2 years.
  • CONCLUSION: This report describes a unique patient with ovarian cancer, who developed iatrogenic leptomeningeal involvement of the lateral ventricule through an indwelling ventriculoperitoneal shunt.
  • [MeSH-major] Meningeal Neoplasms / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Ventriculoperitoneal Shunt / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961641.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. D'Andrea G, Roperto R, Dinia L, Caroli E, Salvati M, Ferrante L: Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases. Neurosurg Rev; 2005 Apr;28(2):120-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases.
  • Ovarian cancer is quite common in women, but brain metastases from ovarian cancer are considered rare.
  • Eleven patients with solitary cerebral metastasis from ovarian epithelial carcinoma were treated at the Neurosurgical Department of University of Rome La Sapienza, between 1980 and 2000.
  • We treated all of the 11 patients by surgical en bloc removal and by postoperative radiotherapy and chemotherapy.
  • Mean survival was 28 months, and the cause of death was recurrence of the systemic disease in all cases.
  • Multimodal treatment by surgery, radiation and chemotherapy is the best choice of treatment and leads to a median survival of about 20 months.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Brain Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4 [12699548.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):67-73 [2026362.001]
  • [Cites] J Neurosurg. 2001 May;94(5):846-8 [11354422.001]
  • [Cites] Surg Neurol. 1993 May;39(5):355-9 [8493593.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2559-62 [2822222.001]
  • [Cites] Cancer. 1978 Feb;41(2):776-83 [630551.001]
  • [Cites] Minerva Ginecol. 1999 Jan-Feb;51(1-2):35-7 [10230243.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):487-92 [12051879.001]
  • [Cites] J Neurooncol. 1987;5(3):211-5 [3681385.001]
  • [Cites] Obstet Gynecol. 1995 Dec;86(6):955-9 [7501347.001]
  • [Cites] Obstet Gynecol. 1986 Dec;68(6):746-50 [3024084.001]
  • [Cites] J Neurooncol. 1994;19(1):75-7 [7815107.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):754-6 [718475.001]
  • [Cites] Neurochirurgie. 1992;38(2):89-97 [1603235.001]
  • [Cites] Obstet Gynecol. 1990 Feb;75(2):278-81 [2300357.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2066-9 [3756821.001]
  • [Cites] J Surg Oncol. 1983 Nov;24(3):192-5 [6685214.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1553-60 [1383433.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Jul;88(7):690-4 [7195732.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2194-9 [2004340.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):571-4 [8573536.001]
  • [Cites] Gynecol Oncol. 2001 Mar;80(3):399-402 [11263939.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):296-300 [2722052.001]
  • [Cites] Neurochirurgie. 1996;42(4-5):216-20 [9084749.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):246-9 [7729743.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):398-406 [3134278.001]
  • [Cites] Obstet Gynecol. 1974 Dec;44(6):873-84 [4373686.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 1;119(7):991-4 [4276313.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):483-6 [10479515.001]
  • [Cites] Gynecol Oncol. 1993 Apr;49(1):37-40 [8482558.001]
  • [Cites] Presse Med. 1998 Jun 6;27(20):966-7 [9767841.001]
  • [Cites] Vascul Pharmacol. 2002 Jun;38(6):349-54 [12529929.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):318-23 [7959302.001]
  • [Cites] Neurosurg Rev. 1994;17(1):83-7 [8078614.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1990 Jul-Aug;36(1-2):203-8 [2194864.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):282-4 [9740706.001]
  • [Cites] Hum Pathol. 1988 Jan;19(1):57-63 [3335391.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):40-3 [8626115.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):133-7 [12468354.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Jpn J Clin Oncol. 1990 Sep;20(3):312-5 [2255108.001]
  • [Cites] Gynecol Oncol. 1987 May;27(1):116-20 [3570045.001]
  • (PMID = 15558348.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Gervais DA, Arellano RS, Mueller PR: Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. AJR Am J Roentgenol; 2006 Sep;187(3):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management.
  • OBJECTIVE: Stages III and IV ovarian cancer are treated with a combination of chemotherapy and resection, in some cases including second and third surgical procedures, to achieve cytoreduction.
  • Percutaneous radiofrequency ablation has proved effective in local control of hepatic tumors.
  • We report early experience with percutaneous radiofrequency ablation in the management of isolated foci of metastatic ovarian cancer and assess the efficacy of the technique in achieving and maintaining local control by percutaneous cytoreduction.
  • CONCLUSION: Percutaneous radiofrequency ablation is effective in achieving local control in selected patients with metastasis from ovarian cancer.
  • In patients with limited macroscopic disease, cytoreduction can be achieved without surgery.
  • [MeSH-major] Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome


82. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L: Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):26-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatic metastasis in patients with ovarian cancer.
  • The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer.
  • From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari.
  • Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse.
  • The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients.
  • Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival.
  • Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670293.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Maekawa H, Sato K, Komatsu Y, Orita H, Sakurada M: Jejunal cancer detected after a resection of bilateral ovarian metastasis: report of a case. Surg Today; 2010 Nov;40(11):1084-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jejunal cancer detected after a resection of bilateral ovarian metastasis: report of a case.
  • Computed tomography and magnetic resonance imaging showed bilateral ovarian tumors.
  • Although these ovarian tumors were suspected of being metastatic, the primary tumor site could not be detected before the bilateral salpingo-oophorectomy.
  • At the time of laparotomy, there was no apparent peritoneal dissemination or ascites.
  • The pathological findings suggested that the ovarian tumors were metastases from cancer of the digestive tract.
  • Positron emission tomography using (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and double-balloon enteroscopy detected jejunal cancer.
  • A second laparotomy for the resection of jejunal cancer was performed.
  • The patient received adjuvant chemotherapy, and there has not been any recurrence for 24 months since the resection was performed.
  • In conclusion, FDG-PET was found to play a valuable role in the detection of the primary tumor.
  • Intensive chemotherapy and surgical treatment also contributed to the long-term survival of the patient.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Jejunal Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Double-Balloon Enteroscopy. Female. Fluorodeoxyglucose F18. Humans. Laparotomy. Magnetic Resonance Imaging. Middle Aged. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):425-8 [15816449.001]
  • [Cites] Tumori. 2006 Nov-Dec;92(6):491-5 [17260489.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Mil Med. 1985 Feb;150(2):105-6 [2983264.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):393-8 [8626898.001]
  • [Cites] Gastrointest Radiol. 1988 Jul;13(3):242-6 [2838370.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):129-32 [7789880.001]
  • [Cites] Jpn J Clin Oncol. 2009 Jan;39(1):54-61 [18997182.001]
  • [Cites] Surg Today. 2009;39(3):235-40 [19280284.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):87-91 [15047218.001]
  • (PMID = 21046510.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


84. Dery MC, Van Themsche C, Provencher D, Mes-Masson AM, Asselin E: Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Reprod Biol Endocrinol; 2007;5:38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro.
  • BACKGROUND: To date, tools to study metastasis in endometrial cancers are insufficiently developed.
  • The aim of this study was to characterize the cell line EN-1078D, a new endometrial carcinoma cell line derived from a metastasis to the ovary.
  • Also, subcutaneous and intravenous injections in nude mice were done to test the tumorigenic and metastatic properties of EN-1078D cells.
  • In addition, this cell line expresses high levels of MMP-2 and MMP-14 mRNA, low levels of TIMP-1 and TIMP-2 transcripts and no detectable levels of MMP-9 mRNA.
  • Moreover, all nude mice developed tumors by subcutaneous injections and cell invasion was observed in vitro in response to TGF-beta 3.
  • Finally, EN-1078D shows sensitivity to drugs commonly used in chemotherapy such as cisplatin and doxorubicin: IC50 of 2.8 microM of cisplatin after 72 hours of exposure and 0.54 microM of doxorubicin after 48 hours.
  • CONCLUSION: Taken together, these results suggest that EN-1078D will be an excellent tool to study the properties of metastatic endometrial cancer cells in vitro and their regulation by sex steroids.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / secondary. Endometrium / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Female. Gonadal Steroid Hormones / metabolism. Gonadal Steroid Hormones / physiology. Humans. Mice. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Tumor Cells, Cultured. Xenograft Model Antitumor Assays / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vitro. 1983 Mar;19(3 Pt 1):147-58 [6339371.001]
  • [Cites] Exp Cell Res. 1994 Dec;215(2):303-9 [7526992.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Oct;28(2):201-12 [3476184.001]
  • [Cites] Asia Oceania J Obstet Gynaecol. 1989 Dec;15(4):403-16 [2624581.001]
  • [Cites] Semin Cancer Biol. 1990 Jun;1(3):165-79 [1715788.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • [Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):293-8 [1282514.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1244-55 [8264658.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] EMBO J. 1996 May 1;15(9):2174-83 [8641283.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):462-7 [9028355.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):449-54 [9449248.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):15879-82 [9632630.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3254-8 [9699651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8 [9811831.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5285-90 [9850049.001]
  • [Cites] Oncology. 1999;56(1):59-65 [9885379.001]
  • [Cites] Subcell Biochem. 1998;31:105-40 [9932491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):668-75 [10080613.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7 [10468583.001]
  • [Cites] J Natl Cancer Inst. 1964 Sep;33:441-56 [14207855.001]
  • [Cites] Rom J Morphol Embryol. 1998 Jan-Dec;44(1-4):101-7 [15678850.001]
  • [Cites] Breast Dis. 2004;20:25-31 [15687704.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):673-5 [15763641.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):637-45 [16407419.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7 [17009991.001]
  • [Cites] Cell. 1999 Oct 29;99(3):323-34 [10555148.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3937-43 [11051241.001]
  • [Cites] Mol Endocrinol. 2000 Dec;14(12):1954-61 [11117526.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):209-12 [11282273.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4576-82 [11389093.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Oct;33(10):960-70 [11470230.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):523-32 [11733966.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):829-44 [11875759.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):104-17 [12703541.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Jun;22(2):265-71 [12866577.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):803-10 [12888921.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):428-65 [12920150.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):109-21 [14597237.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):719-25 [14766275.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):179-86 [15036258.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1311-24 [15067356.001]
  • [Cites] Mol Cancer. 2004 Mar 11;3:7 [15016316.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):699-704 [15350361.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] Cancer. 1971 May;27(5):1064-73 [4325742.001]
  • [Cites] Am J Obstet Gynecol. 1972 Dec 15;114(8):1012-9 [4673779.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4794-802 [17150964.001]
  • [Cites] Gynecol Oncol. 1984 Feb;17(2):213-30 [6706226.001]
  • (PMID = 17894888.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Other-IDs] NLM/ PMC2092433
  •  go-up   go-down


85. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • They are helpful in the selection of treatment; provide insights into the disease process and the therapic response.
  • The number of possibility useful prognosis factors in the colorectal cancer is large.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • RESULTS: Locoregional extension was found in 18 cases and metastatic extension in 45 cases with hepatic metastasis in 37 cases and pulmonary metastasis in 8 cases.
  • There were 6 cases of peritoneal localized carcinosis and 6 cases of ovary metastasis.
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Akiba Y, Watanabe C, Takada Y, Naito K, Aoki D, Mukai M, Kato S, Hibi T, Ishii H: [A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum]. Gan To Kagaku Ryoho; 2003 Feb;30(2):277-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum].
  • Survival of patients with advanced gastric cancer with Krukenberg's tumor is poor.
  • We report the case of a good response in a 37-year-old woman who had type 4 gastric cancer, diagnosed after the operation of Krukenberg's tumor, and then was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with a low-dose cisplatinum (CDDP).
  • Endoscopic gastric biopsy showed signet-ring cell adenocarcinoma and moderately differentiated tubular adenocarcinoma, and computed tomography (CT) showed the para-aortic lymph node metastasis before the chemotherapy.
  • After the first course, gastric biopsy did not show any cancer cells and lymph node metastasis had disappeared.
  • Serum CA19-9 decreased gradually week by week during the chemotherapy, even during the washout period after the first course, and was normalized after two courses.
  • This case suggests that the combination of TS-1 and low-dose CDDP is effective against type 4 advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Krukenberg Tumor / surgery. Neoplasms, Multiple Primary. Ovarian Neoplasms / surgery. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Infusions, Intravenous. Lentinan / administration & dosage. Ondansetron / administration & dosage. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610879.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 4AF302ESOS / Ondansetron; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


87. Takenoue T, Yamada Y, Miyagawa S, Akiyama Y, Nagawa H: Krukenberg tumor from gastric mucosal carcinoma without lymphatic or venous invasion: report of a case. Hepatogastroenterology; 2001 Jul-Aug;48(40):1211-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor from gastric mucosal carcinoma without lymphatic or venous invasion: report of a case.
  • A 49-year-old woman was admitted because of early gastric carcinoma.
  • In the resected specimen, gastric mucosal carcinoma without lymph node metastases was located in the prepyloric region.
  • Histologic type was moderately differentiated adenocarcinoma and signetring cell carcinoma, and there was no lymphatic or venous invasion.
  • One year after operation, a left ovarian tumor was detected.
  • Pathological findings revealed Krukenberg tumors originating from the gastric carcinoma in the bilateral ovaries.
  • One year after the second operation, a hard mass due to cancer recurrence developed in the pelvis with symptoms including tenesmus and abdominal pain.
  • Chemotherapy and palliative colostomy were performed.
  • We experienced a rare case of Krukenberg tumor with two interesting points; its origin was gastric mucosal carcinoma without lymphatic or venous invasion, and the patient survived for more than four years after the diagnosis.
  • [MeSH-major] Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Female. Gastrectomy. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Krukenberg carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11490837.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Mrad K, Morice P, Fabre A, Pautier P, Lhommé C, Duvillard P, Sabourin JC: Krukenberg tumor: a clinico-pathological study of 15 cases. Ann Pathol; 2000 May;20(3):202-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor: a clinico-pathological study of 15 cases.
  • Krukenberg tumor clinically mimics primary ovarian cancer.
  • We report a series of 15 cases of Krukenberg tumor.
  • Most ovarian tumors (14/15) were bilateral.
  • A primary digestive tumor was diagnosed pre-operatively in 3 cases, per-operatively in 3 cases and post-operatively in 4 cases.
  • No primary tumor was identified in the 5 other cases.
  • Histological diagnosis of Krukenberg tumor is usually easy either on paraffin or frozen sections.
  • Two main histological types were found in our series : the classic form with sarcoma-like storiform tumoral stroma and an alternative cellular-acellular pattern.
  • Nor surgery, neither chemotherapy is efficient but bilateral oophorectomy should be proposed in post-menopausal women with gastric linitis removed surgically.
  • [MeSH-major] Breast Neoplasms / diagnosis. Colonic Neoplasms / diagnosis. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10891713.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


89. Yildirim Y, Sanci M: The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer. Arch Gynecol Obstet; 2005 Jun;272(1):31-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer.
  • INTRODUCTION: Pancreatic metastasis of ovarian cancer is extremely rare and its therapeutic approach is not well documented.
  • The objective of this study is to evaluate the feasibility and morbidity of pancreatic resection as a component of extensive cytoreductive surgery in epithelial ovarian cancer (EOC) patients with pancreas metastasis.
  • Six (6.12%) of these patients had pancreatic tail metastasis and were operated on using the distal pancreatectomy.
  • RESULTS: Preoperatively, only 1 (16.7%) of the 6 patients had signs of metastasis to the pancreas on computed tomography (CT).
  • Optimal cytoreduction (absent or < or =1 cm macroscopic residual tumor size) was achieved in all patients.
  • All patients received six cycles of platinum-based adjuvant chemotherapy following a cytoreductive operation.
  • CONCLUSION: In conclusion, if optimal cytoreduction is foreseen in advanced epithelial ovarian cancer with pancreatic tail metastasis, distal pancreatectomy should be kept in mind.
  • This procedure has acceptable morbidity and seems to be an attribute for survival.
  • [MeSH-major] Adenocarcinoma / surgery. Ovarian Neoplasms / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Middle Aged. Postoperative Complications / epidemiology. Reoperation. Survival Rate. Tomography, X-Ray Computed


90. Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS: The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):97-101
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries.
  • STUDY DESIGN: From September 1994 to December 2006, 158 patients with pathologically confirmed metastatic tumors to the ovaries at Samsung Medical Center (SMC) were included in this study.
  • RESULTS: The primary tumor origin was mostly stomach (73 cases) and colon (61 cases).
  • Krukenberg tumor (pathologically proven signet ring cell carcinoma) was found in 34 cases: stomach (25), colon (2), appendix (1), and unknown (6).
  • Residual disease after surgery was >2 cm in 65 (41.1%) cases and <2 cm in 93 (58.9%) cases.
  • The overall 5-year survival was 7.2% and the median survival time was 15 months.
  • The median survival times according to the primary tumor site showed significant differences (p=0.002) and were as follows: stomach 12 months, colon 17 months.
  • The median survival in cases with residual disease <2 cm vs. >2 cm was 26 months vs. 15 months (p=0.017) and the median survival with vs. without adjuvant chemotherapy was 16 months vs. 10 months (p=0.001).
  • However, age, bilateral tumors, chronology of diagnosis and mass size did not affect survival.
  • CONCLUSION: Cytoreductive surgery and post-operative adjuvant chemotherapy had a beneficial effect on survival in selected patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Krukenberg Tumor / secondary. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018420.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


91. Singhal SR, Nanda S, Chaudhry P, Sen J, Singhal SK: Metastatic bilateral malignant ovarian tumors associated with pregnancy. Taiwan J Obstet Gynecol; 2009 Jun;48(2):167-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic bilateral malignant ovarian tumors associated with pregnancy.
  • OBJECTIVE: Krukenberg tumors in pregnancy are extremely rare.
  • CASE REPORT: A 20-year-old, primigravida with bilateral malignant ovarian tumors, who received no prior antenatal care, was presented with intestinal obstruction at 5 months' gestation.
  • The patient aborted spontaneously and postoperatively, and was treated with adjuvant chemotherapy.
  • CONCLUSION: Because platinum-based chemotherapy can be safely given during pregnancy, hysterectomy can be avoided in cases of bilateral malignant ovarian tumors if the uterus is not grossly involved, so allowing preservation of an existing pregnancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / pathology. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic / ultrasonography
  • [MeSH-minor] Abortion, Spontaneous. Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Omentum / surgery. Ovariectomy. Pregnancy. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Taiwan J Obstet Gynecol. 2011 Sep;50(3):405-6; author reply 407 [22030067.001]
  • (PMID = 19574181.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Morimoto Y, Imai S, Matsumoto T, Kunisue M, Kawasaki S, Yamaguchi K, Okabe M, Kawamoto K, Ito T, Ogasawara K: [A case of Stage IV non-operated advanced breast cancer with local recurrence thirteen years after initial therapy]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1693-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Stage IV non-operated advanced breast cancer with local recurrence thirteen years after initial therapy].
  • A 73-year-old woman underwent chemotherapy, radiotherapy, and hormonal therapies for right advanced breast cancer (T4, N3, M1, Stage IV) in 1993.
  • For adjuvant therapies, she had been treated with hormonal therapies for five years until 2003.
  • After the interruption of hormonal therapies, the serum levels of tumor markers had been elevated, and she had a right axillary local recurrence and a right ovarian metastasis detected by a FDG-PET/CT in February 2006.
  • The right axillary local recurrence lesion was then resected, and she has since been treated with hormonal therapy of aromatase inhibitor (AI).
  • The serum levels of tumor markers have been remarkably reduced, and FDG-PET/CT has showed the disappearance of the right axillary local recurrence, and the decrease of FDG accumulation of the right ovarian metastases in February 2007.
  • We present a case of non-operated advanced breast cancer with local recurrence surviving successfully long term when treated with AI.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Aromatase Inhibitors / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940393.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Biomarkers, Tumor
  •  go-up   go-down


93. Baba Y, Ishikawa S, Ikeda K, Honda S, Miyanari N, Iyama K, Baba H: A patient with 43 synchronous early gastric carcinomas with a Krukenberg tumor and pericardial metastasis. Gastric Cancer; 2007;10(2):135-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with 43 synchronous early gastric carcinomas with a Krukenberg tumor and pericardial metastasis.
  • A 53-year-old Japanese woman with bilateral ovarian tumors consulted our department.
  • Gastroendoscopy disclosed 16 superficial depressed gastric lesions, and the histopathological diagnosis of the biopsy specimens was poorly differentiated adenocarcinoma and signet-ring cell carcinoma.
  • Computed tomography (CT), ultrasonography (US), and positron emission tomography (PET) examinations revealed no other metastasis except for that observed in the ovaries.
  • We performed a total gastrectomy with radical lymph node dissection and bilateral ovarian resection.
  • Cancer cell invasion in the lymphatics was detected only in the submucosal region beneath the main tumor.
  • Both ovarian tumors were diagnosed as metastasis of signet-ring cell carcinoma (Krukenberg tumor).
  • Adjuvant chemotherapy with irinotecan (CPT-11) and low-dose cisplatin (CDDP) was given on an outpatient basis, but 1 year after the surgery, carcinomatous pericarditis occurred.
  • [MeSH-major] Adenocarcinoma / secondary. Heart Neoplasms / secondary. Krukenberg Tumor / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary. Pericardium / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Cardiac Tamponade / etiology. Cardiac Tamponade / surgery. Fatal Outcome. Female. Gastrectomy. Humans. Lymphatic Metastasis / pathology. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jun 1;65(11):2602-5 [2337877.001]
  • [Cites] J Gastroenterol. 1999 Apr;34(2):250-2 [10213127.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):512-6 [7550863.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):678-85 [12576435.001]
  • [Cites] J Surg Oncol. 1996 May;62(1):57-61 [8618403.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Gastroenterology. 1987 Sep;93(3):506-14 [3301516.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Gastroenterol. 2003;38(12):1176-80 [14714257.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1697-1704 [7370925.001]
  • [Cites] Gastroenterology. 1957 Jun;32(6):1095-103 [13438166.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1211-4 [11490837.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):560-5 [3791165.001]
  • [Cites] Br J Surg. 1989 Mar;76(3):237-40 [2720317.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10 (3):687-91 [12684644.001]
  • (PMID = 17577625.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH: Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol; 2004 Aug;94(2):477-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer.
  • OBJECTIVE: An optimal treatment strategy for ovarian metastases of gastric cancer has not been clearly established.
  • The aim of this study was to examine the role of a metastasectomy in the management of metachronous Krukenberg tumors after curative surgery for gastric cancer.
  • METHODS: Among 1235 female patients who had undergone a curative gastric resection for stomach cancer between 1987 and 1998, 54 (4.4%) developed Krukenberg tumors as a first recurrence without evidence of a distant metastasis.
  • RESULTS: The clinicopathological features of Krukenberg tumors as well as those of the primary cancers in the two groups were similar.
  • All 33 patients in the resection group underwent subsequent adjuvant chemotherapy, including the 7 who received intraperitoneal chemotherapy.
  • The 21 patients in the non-resection group were managed by either systemic chemotherapy (n = 16) or supportive care (n = 5) alone.
  • The median survival time in the resection group was 17 months (95% confidence interval, 10-24 months), which was significantly longer than that in the non-resection group, 3 months (95% confidence interval, 2-4 months) (P < 0.001).
  • CONCLUSION: Our results suggest that a metastasectomy was associated with an improved survival in patients with metachronous Krukenberg tumors from gastric cancer.
  • These data offer a strong argument in favor of performing metastasectomy for Krukenberg tumors in the absence of an obvious distant metastasis.
  • [MeSH-major] Krukenberg Tumor / secondary. Krukenberg Tumor / surgery. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297191.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Sotiropoulos GC, Kaiser GM, Lang H, Treckmann J, Brokalaki EI, Pottgen C, Gerken G, Paul A, Broelsch CE: Staging laparoscopy in gastric cancer. Eur J Med Res; 2005 Feb 28;10(2):88-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging laparoscopy in gastric cancer.
  • BACKGROUND: As patients with gastric cancer are offered choices between surgical resection, neoadjuvant or palliative chemotherapy, or symptomatic relief alone, the need for accurate preoperative staging becomes apparent.
  • METHODOLOGY: Staging laparoscopy was performed in 45 patients with potentially resectable gastric cancer as determined by physical examination, gastroscopy, endosonography, transcutaneous ultrasonography and current generation computed tomography.
  • Conventional clinic staging and laparoscopic staging according to the Tumor-Node-Metastases classification of the International Union against Cancer were registered separately on a database.
  • In 10 patients of them peritoneal seeding was first found during laparoscopy, whereas additional liver metastases were detected in 3 patients and Krukenberg's tumor in one.
  • As a consequence, the therapy planning was changed and laparotomy was avoided in 14 of these patients as the first operative procedure.
  • Sensitivity of clinical staging was especially poor for stage IV tumors (5.3%) and for the majority of stage IIIB tumors (42.9%).
  • CONCLUSIONS: The value of laparoscopy in staging patients with gastric carcinoma could be demonstrated in this study.
  • It is a safe and effective staging modality, helping to avoid unnecessary laparotomies and providing new means of directing appropriate treatment strategy.
  • [MeSH-major] Gastroscopy. Liver Neoplasms / pathology. Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817429.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Husein-ElAhmed H, Aneiros-Fernandez J, Arias-Santiago S, Naranjo-Sintes R: Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma. Int J Dermatol; 2010 Sep;49(9):1045-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Sister Mary Joseph's Nodule / secondary. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Capecitabine. Carboplatin / therapeutic use. Colonoscopy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neprilysin / analysis. Organoplatinum Compounds / therapeutic use. Paclitaxel / therapeutic use. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome. Umbilicus / pathology. Vimentin / analysis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883267.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 0 / WT1 Proteins; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; EC 3.4.24.11 / Neprilysin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


97. Fan F, Hernandez-Rios P, Damjanov I, Dusing RW: Metastasis of ovarian ependymoma to the liver diagnosed by fine needle aspiration cytology. Acta Cytol; 2006 Nov-Dec;50(6):709-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of ovarian ependymoma to the liver diagnosed by fine needle aspiration cytology.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Ependymoma / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Cysts / pathology. Diagnosis, Differential. Drug Therapy. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152290.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement